

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 21, 2001, 10:34:49 ; Search time 187.98 Seconds
(without alignments)
9382.784 Million cell updates/sec

Title: US-09-587-111-4

Perfect score: 2809
Sequence: 1 ggctagcctgtcctgacagc.....aaaaaaaaaaaaaaaaaaaaa 2809

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 730101 seqs, 313950809 residues

Total number of hits satisfying chosen parameters: 1460202

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

N_Geneseq_0601:*

1: /SIDSI/gcgdata/geneseq/geneseqn/NA1980.DAT:*

2: /SIDSI/gcgdata/geneseq/geneseqn/NA1981.DAT:*

3: /SIDSI/gcgdata/geneseq/geneseqn/NA1982.DAT:*

4: /SIDSI/gcgdata/geneseq/geneseqn/NA1983.DAT:*

5: /SIDSI/gcgdata/geneseq/geneseqn/NA1984.DAT:*

6: /SIDSI/gcgdata/geneseq/geneseqn/NA1985.DAT:*

7: /SIDSI/gcgdata/geneseq/geneseqn/NA1986.DAT:*

8: /SIDSI/gcgdata/geneseq/geneseqn/NA1987.DAT:*

9: /SIDSI/gcgdata/geneseq/geneseqn/NA1988.DAT:*

10: /SIDSI/gcgdata/geneseq/geneseqn/NA1989.DAT:*

11: /SIDSI/gcgdata/geneseq/geneseqn/NA1990.DAT:*

12: /SIDSI/gcgdata/geneseq/geneseqn/NA1991.DAT:*

13: /SIDSI/gcgdata/geneseq/geneseqn/NA1992.DAT:*

14: /SIDSI/gcgdata/geneseq/geneseqn/NA1993.DAT:*

15: /SIDSI/gcgdata/geneseq/geneseqn/NA1994.DAT:*

16: /SIDSI/gcgdata/geneseq/geneseqn/NA1995.DAT:*

17: /SIDSI/gcgdata/geneseq/geneseqn/NA1996.DAT:*

18: /SIDSI/gcgdata/geneseq/geneseqn/NA1997.DAT:*

19: /SIDSI/gcgdata/geneseq/geneseqn/NA1998.DAT:*

20: /SIDSI/gcgdata/geneseq/geneseqn/NA1999.DAT:*

21: /SIDSI/gcgdata/geneseq/geneseqn/NA2000.DAT:*

22: /SIDSI/gcgdata/geneseq/geneseqn/NA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2809	100.0	2809	21	AAA30254
2	2766.8	98.5	2783	20	AAZ22829
3	2720.6	96.9	2765	21	AAA14874
4	2604.8	92.7	2779	19	AAV59691
5	2462.2	87.7	2469	22	AAAC60297
6	2385.2	84.9	2860	19	AAV59807
7	2378.4	84.7	2380	20	AAZ87492
8	2347.8	83.6	2351	20	AAZ07114
9	2333.4	83.1	2348	20	AAZ07116
10	1544.2	55.0	2736	20	AAZ87478
11	1544.2	55.0	2736	20	AAZ19730

12	1102.4	39.2	1794	21	AAA30256	Rat partial VR-2 c
13	1055	37.6	1489	21	AAA30255	Human VR-2 (altern
14	790.4	28.1	885	20	AAZ07115	Human vanilloid re
15	787.8	28.0	884	20	AAZ87501	Human vanilloid re
16	787.8	28.0	884	20	AAZ19741	Human VRP-1 (VR2)
17	765.8	27.3	876	19	AAV59808	Human secreted pro
18	662.4	23.6	3909	21	AAA30253	Human VR-1 coding
19	662.4	23.6	4365	21	AAA29172	Human vanilloid re
20	660.8	23.5	2520	21	AAAC66463	Human vanilloid re
21	660.8	23.5	2544	20	AAZ87491	Human capsaicin re
22	660.8	23.5	3500	20	AAZ10065	CDNA encoding a hu
23	660.8	23.5	4803	20	AAZ10062	CDNA encoding a hu
24	660.8	23.5	4824	21	AAAC66464	Human vanilloid re
25	660	23.5	4803	20	AAZ10063	CDNA encoding a pa
26	651.8	23.2	2880	20	AAZ87477	Rat capsaicin rece
27	651.8	23.2	2880	20	AAZ19729	Rat VR1 capsaicin
28	597.6	21.3	764	20	AAZ87500	Human vanilloid re
29	597.6	21.3	764	20	AAZ19740	Human VRP-1 (VR2)
30	578	20.6	768	20	AAZ87480	Human vanilloid re
31	578	20.6	768	20	AAZ19732	Human VRP-1 capsa
32	559	19.9	4118	21	AAA29173	Human vanilloid re
33	535.4	19.1	2845	20	AAZ87502	Chicken capsaicin
34	535.4	19.1	2845	20	AAZ19742	Chicken VR1 capsa
35	501.4	17.8	650	20	AAZ87481	Human vanilloid re
36	501.4	17.8	650	20	AAZ19733	Human VRP-1 capsa
37	376.4	13.4	403	21	AAZ80276	Human colon cancer
38	346	12.3	350	20	AAZ87499	Human vanilloid re
39	346	12.3	350	20	AAZ19739	Human VRP-1 (VR2)
40	234.6	8.4	273	20	AAZ87479	Human vanilloid re
41	234.6	8.4	273	20	AAZ19731	Human VRP-1 capsa
42	162.4	5.8	450	20	AAZ87498	Mouse capsaicin re
43	162.4	5.8	471	20	AAZ19736	Mouse DNA sequence
44	160.8	5.7	471	20	AAZ87497	Mouse capsaicin re
45	160.8	5.7	471	20	AAZ19735	Mouse VR1 capsaicl

ALIGNMENTS

RESULT 1

AAA30254

ID AAA30254 standard; CDNA: 2809 BP.

XX

AC AAA30254;

XX

DT 05-SEP-2000 (first entry)

XX

DE Human VR-2 coding sequence.

XX

KW VR-2; human; vanilloid receptor; nociceptor; pain signalling;

KW hyperalgesia; musculoskeletal disorder; neuropathic pain;

KW chromosome 17p11-12; gene therapy; ss.

XX

OS Homo sapiens.

XX

XX

Key Location/Qualifiers

FT CDS 361..2655

FT

FT /*tag=a

FT /product="VR-2"

FT /note="This region is specifically claimed"

XX

PN W0200029577-A1.

XX

XX

PD 25-MAY-2000.

XX

XX

PE 12-NOV-1999; 99WO-US26701.

XX

XX

PR 13-NOV-1998; 98US-0108322.

PR 28-DEC-1998; 98US-0114078.

PR 26-FEB-1999; 99US-0258633.

PR 19-OCT-1999; 99US-0421134.

XX

XX

PA (MILL-) MILLENNIUM PHARM INC.

XX Curtis RAJ;
PI
XX
DR WPI: 2000-387790/33.
DR P-PSDB: AAY97358.
XX
PT New capsatin/vanilloid receptor polynucleotides and polypeptides, used
PT to modulate pain signalling mechanisms
XX
PS Claim 1; Fig 2; 183pp: English.
XX
XX The present sequence is the coding sequence for human
CC Capsaicin/vanilloid receptor VR-2, which is involved in pain signalling.
CC The sequence was isolated by searching a heart library for genes
CC encoding novel receptors of the capsaicin/vanilloid family, and has been
CC shown to be located at chromosome 17p11-12. This region has been
CC associated with myasthenia gravis, Smith-Magenis syndrome, CORD5,
CC Cone-rod dystrophy, choroidal dystrophy, central areolar and retinal
CC cone dystrophy, and it is possible that the protein may be used to treat
CC or diagnose these disorders. In addition, the gene, protein and its
CC antibodies can be used to diagnose and treat hyperalgesia, inflammation,
CC infection, ischaemia, joint pain, tooth pain, headaches, pain associated
CC with surgery or neuropathic pain, possibly via the use of gene therapy.
XX
SQ Sequence 2809 BP; 601 A; 825 C; 798 G; 585 T; 0 other;

Query Match 100.0%; Score 2809; DB 21; Length 2809;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2809; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ggcctagcgtctcctcagagagagagtaagctccgtctccacagctgcggtgcca 60
DB 1 ggcctagcgtctcctcagagagagagtaagctccgtctccacagctgcggtgcca 60
QY 61 ggtggagctgaggtgagcagagagacagaaactgtctgtgagcttaagtacagct 120
DB 61 ggtggagctgaggtgagcagagagacagaaactgtctgtgagcttaagtacagct 120
QY 121 ggggagggaggttcgagcgcctctctgtctgagcggcgagccctcccgcttcaact 180
DB 121 ggggagggaggttcgagcgcctctctgtctgagcggcgagccctcccgcttcaact 180
QY 181 tctctccgagagccctcgtctactgagagctccggatcccaagagccgacacccctgac 240
DB 181 tctctccgagagccctcgtctactgagagctccggatcccaagagccgacacccctgac 240
QY 241 ctcaagctcggggctcagctcagcacaacacgacgacgagctggagagagagacagac 300
DB 241 ctcaagctcggggctcagctcagcacaacacgacgacgagctggagagagagacagac 300
QY 301 ccttgacatctcactctgacagagagctctgtgtgagcagagagctctctctctttag 360
DB 301 ccttgacatctcactctgacagagagctctgtgtgagcagagagctctctctctttag 360
QY 361 atgacctcaccctccagcctccagctttcaggtttgagacatlaagtatgagagcagaag 420
DB 361 atgacctcaccctccagcctccagctttcaggtttgagacatlaagtatgagagcagaag 420
QY 421 gatggtctcgaagcgagacagagaaagtgtgatttggagcggtctccctccatgag 480
DB 421 gatggtctcgaagcgagacagagaaagtgtgatttggagcggtctccctccatgag 480
QY 481 tcaacattccagagcgagagacggaattcgccctccagataagatccaactcaactac 540
DB 481 tcaacattccagagcgagagacggaattcgccctccagataagatccaactcaactac 540
QY 541 cgaagagagagagtgagcagctcagccgagatccaacagatttgacgagatcggtcttc 600
DB 541 cgaagagagagagtgagcagctcagccgagatccaacagatttgacgagatcggtcttc 600
QY 601 aatgcggtctcccggtgttcccgagagatctgtgtgacttccagatcaactgagcaag 660
DB 601 aatgcggtctcccggtgttcccgagagatctgtgtgacttccagatcaactgagcaag 660

DB 601 aatgcggtctcccggtgttcccgagagatctgtgtgacttccagatcaactgagcaag 660
QY 661 accagcaagtactcaccgactcgtgatatcacagaggtctcccaagttaagaagtctccg 720
DB 661 accagcaagtactcaccgactcgtgatatcacagaggtctcccaagttaagaagtctccg 720
QY 721 atgaaggtctgtgtaaccttaagagcagagatcaatgacctctctcagctgcagcag 780
DB 721 atgaaggtctgtgtaaccttaagagcagagatcaatgacctctctcagctgcagcag 780
QY 781 atcagacaggactctgcaatctcagccctgtgtaaatgcccagtgcacagatgactat 840
DB 781 atcagacaggactctgcaatctcagccctgtgtaaatgcccagtgcacagatgactat 840
QY 841 taccagggccacagcctctgcacatcgccatggaagagagagctcagatgtgtgaaag 900
DB 841 taccagggccacagcctctgcacatcgccatggaagagagagctcagatgtgtgaaag 900
QY 901 ctctgtgtgagagatgggccaatgtgcatgcccggcctgcgagcgtctctccagaag 960
DB 901 ctctgtgtgagagatgggccaatgtgcatgcccggcctgcgagcgtctctccagaag 960
QY 961 ggccaaggagactgtcttatttcgtgtgagctacccctctctgtgcccgttgcacaaag 1020
DB 961 ggccaaggagactgtcttatttcgtgtgagctacccctctctgtgcccgttgcacaaag 1020
QY 1021 cagtggtgtgtgttaagctacccctctggaagaccacacagccgacgctgcagagcc 1080
DB 1021 cagtggtgtgtgttaagctacccctctggaagaccacacagccgacgctgcagagcc 1080
QY 1081 actgactccagggcacaacagctcctgcatgcccctagtgatgactcggacaactcagct 1140
DB 1081 actgactccagggcacaacagctcctgcatgcccctagtgatgactcggacaactcagct 1140
QY 1141 gagaacattgcaactgtgtgacacagatgatatgaggtctcccaagcttgggccccttc 1200
DB 1141 gagaacattgcaactgtgtgacacagatgatatgaggtctcccaagcttgggccccttc 1200
QY 1201 tggcctacggtgagcttlaagagacatccgaacctcagaatctcagctctcgaagctg 1260
DB 1201 tggcctacggtgagcttlaagagacatccgaacctcagaatctcagctctcgaagctg 1260
QY 1261 ggcgcgaagagagggcagaagctcagagatcttcagggacatcctgcaagcgaggtttcaga 1320
DB 1261 ggcgcgaagagagggcagaagctcagagatcttcagggacatcctgcaagcgaggtttcaga 1320
QY 1321 ctgagccacctctccggaagtctcaacgagtggtgtatgaggtctccgggtgtctgcg 1380
DB 1321 ctgagccacctctccggaagtctcaacgagtggtgtatgaggtctccgggtgtctgcg 1380
QY 1381 tatgacctgtgctctgtgacagcgtgtgagagaaactcagctctgtagatcatgtgcttt 1440
DB 1381 tatgacctgtgctctgtgacagcgtgtgagagaaactcagctctgtagatcatgtgcttt 1440
QY 1441 cattgcaagagcccgacacgacacgcaatggtcttcttggagccctctgacaactgtctg 1500
DB 1441 cattgcaagagcccgacacgacacgcaatggtcttcttggagccctctgacaactgtctg 1500
QY 1501 cagggcgaatgtggtatctgtctatcccaaggtctctttaaactctctgtgtatctgatac 1560
DB 1501 cagggcgaatgtggtatctgtctatcccaaggtctctttaaactctctgtgtatctgatac 1560
QY 1561 tacatgtatcattccacgctgttgctctacatcaacccatccctgaaagagcagcgcc 1620
DB 1561 tacatgtatcattccacgctgttgctctacatcaacccatccctgaaagagcagcgcc 1620
QY 1621 cctcactctgaagcgaggttggaaactccatgctgtgacgggccaacatcctatctctg 1680
DB 1621 cctcactctgaagcgaggttggaaactccatgctgtgacgggccaacatcctatctctg 1680
QY 1681 ctgaggggagatctactcctctgtggcagcgtgtgttactcttgcggcgccaagtgttc 1740
DB 1681 ctgaggggagatctactcctctgtggcagcgtgtgttactcttgcggcgccaagtgttc 1740

[illegible]

RESULT	2
AA422829	standard: cDNA; 2783 BP.
XX	
AC	AA422829;
XX	
DT	06-DEC-1999 (first entry)
XX	
DE	Human vanilloid receptor-like cation channel (hVRCC) cDNA.
XX	
KW	Vanilloid; capsaicin; neuron; selective; calcium; cation; receptor; pain;
XX	
OS	Inflammation; brain disease; cancer; autoimmune disorder; ds.
XX	
XX	Homo sapiens.
XX	
FT	Key
FT	5'UTR
FT	CDS
FT	Location/Qualifiers
FT	1..360
FT	/*tag= a
FT	361..2652
FT	/*tag= b
FT	/product= "Human vanilloid receptor-like cation channel"
FT	replace (374, T)
FT	/*tag= e
FT	replace (750, G)
FT	/*tag= f
FT	replace (787, C)
FT	/*tag= g
FT	replace (1612, CACG)
FT	/*tag= h
FT	2653..2783
FT	/*tag= i
XX	
PN	W09946377-A2.
XX	
PD	16-SEP-1999.
XX	
PE	10-MAR-1999; 99WO-EP01550.
XX	
PR	11-MAR-1998; 98EP-0400565.
XX	
PA	(SNFI) SANOFI-SYNTHELABO.
XX	
PI	Partisetti M, Renard S;
XX	
DR	WP1: 1999-571722/48.
XX	
DR	P-PSDB; AAY42308.
XX	
PT	New receptor-like channel polypeptide and polynucleotide useful for
PT	prevention and treatment of cancer, autoimmune disease, brain disease
XX	
XX	and ulcers -
XX	
PS	Claim 5; Page 14; 50pp; English.
XX	
CC	This sequence represents a human vanilloid receptor-like cation channel
CC	(hVRCC) cDNA. This channel is activated by vanilloids such as capsaicin
CC	and resiniferatoxin, and is expressed in a variety of tissues,
CC	particularly in nervous tissue such as the amygdala, substantia nigra,
CC	thalamus, dorsal root ganglia and spinal cord. Vanilloids are natural
CC	compounds which are known to trigger cation permeability in the
CC	peripheral neurons involved in transmission of noxious stimuli (e.g.,
CC	mechanical, chemical or thermal). A recently discovered rat
CC	vanilloid-gated cation channel, which is highly expressed in dorsal root
CC	ganglia, has six putative transmembrane domains, giving it significant
CC	structural homology with "store-operated" calcium channels, and is highly
CC	selective for calcium ions. hVRCC and nucleotides encoding it can be used
CC	in prevention, diagnosis or therapy of disorders that may be associated
CC	with an excess or deficiency of hVRCC. Disorders detected or treated
CC	using hVRCC proteins, nucleotides or antagonists include chronic
CC	inflammation, acute and chronic pain, brain diseases, abnormal
CC	proliferation and cancer, ulcers, autoimmune diseases, control of viscera
CC	innervated by the dorsal root ganglia neurons, to mimic or antagonise
CC	effect of endogenous neurotransmitters and hormones, and to inhibit graft
CC	

CC rejection by promoting immunosuppression. Nucleotide sequences encoding
CC hVRFC are also useful for chromosome localisation.
XX
SQ Sequence 2783 BP; 578 A; 824 C; 796 G; 585 T; 0 other;

Query Match 98.5%; Score 2766.8; DB 20; Length 2783;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 2781; Conservative 0; Mismatches 2; Indels 3; Gaps 1;

QY 1 ggttaacgtctctgacagagagatlaagctcccggtttccacgtgctgagctgcca 60
DB 1 ggctaacctctgctcgcagagggagagtaagctcccggtttccacgtgctgagc 60
QY 61 ggtggtctgaggtgagacagagacacacacacacacacacacacacacacac 120
DB 61 ggtggtctgaggtgagacagagacacacacacacacacacacacacacacac 120
QY 121 gggagagaggttcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 180
DB 121 gggagagaggttcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 180
QY 181 tctctccgcagacccctgctacttgaagagctccgcgcgcgcgcgcgcgcgcgc 240
DB 181 tctctccgcagacccctgctacttgaagagctccgcgcgcgcgcgcgcgcgcgc 240
QY 241 ctgacgtctgcggtctcagctcagacacacacacacacacacacacacacac 300
DB 241 ctgacgtctgcggtctcagctcagacacacacacacacacacacacacacac 300
QY 301 ccttgacatctccatctgacacagagctcgtgacacacacacacacacacac 360
DB 301 ccttgacatctccatctgacacagagctcgtgacacacacacacacacacac 360
QY 361 atgaactcaccctccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 420
DB 361 atgaactcaccctccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 420
QY 421 gatggtctgaggtgagacagagagagagagagagagagagagagagagagag 480
DB 421 gatggtctgaggtgagacagagagagagagagagagagagagagagagagag 480
QY 481 tcaacgttccaggtcgagagacagagagagagagagagagagagagagagag 540
DB 481 tcaacgttccaggtcgagagacagagagagagagagagagagagagagagag 540
QY 541 cgaag 600
DB 541 cgaag 600
QY 601 aatggtctctccgc 660
DB 601 aatggtctctccgc 660
QY 661 accag 720
DB 661 accag 720
QY 721 atgaagaggtgtgacacacacacacacacacacacacacacacacacacac 780
DB 721 atgaagaggtgtgacacacacacacacacacacacacacacacacacacac 780
QY 781 atcgag 840
DB 781 atcgag 840
QY 841 taacgag 900
DB 841 taacgag 900
QY 901 ctctctgtgag 960
DB 901 ctctctgtgag 960

QY 961 ggccaaggagactgtcttattatctggtgagctacccctctcttggcgcttgaccag 1020
DB 961 ggccaaggagactgtcttattatctggtgagctacccctctcttggcgcttgaccag 1020
QY 1021 cagtgagatgtgtaagctactcctctgagagacacacacacacacacacacac 1080
DB 1021 cagtgagatgtgtaagctactcctctgagagacacacacacacacacacacac 1080
QY 1081 acggtctccagggcagacacacacacacacacacacacacacacacacacac 1140
DB 1081 acggtctccagggcagacacacacacacacacacacacacacacacacacac 1140
QY 1141 gagaacatgacatgtgacacacacacacacacacacacacacacacacacacac 1200
DB 1141 gagaacatgacatgtgacacacacacacacacacacacacacacacacacacac 1200
QY 1201 tgcctacacgtgacgtctgagacacacacacacacacacacacacacacacac 1260
DB 1201 tgcctacacgtgacgtctgagacacacacacacacacacacacacacacacac 1260
QY 1261 gccgcgaag 1320
DB 1261 gccgcgaag 1320
QY 1321 ctgagcaccttctccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 1380
DB 1321 ctgagcaccttctccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 1380
QY 1381 tatgacgtgctctgtgacacacacacacacacacacacacacacacacacacac 1440
DB 1381 tatgacgtgctctgtgacacacacacacacacacacacacacacacacacacac 1440
QY 1441 catgcaagagccgc 1500
DB 1441 catgcaagagccgc 1500
QY 1501 cagggcaaatgagatctgctacacacacacacacacacacacacacacacacac 1560
DB 1501 cagggcaaatgagatctgctacacacacacacacacacacacacacacacacac 1560
QY 1561 taacgttcatcttccacacacacacacacacacacacacacacacacacacac 1620
DB 1561 taacgttcatcttccacacacacacacacacacacacacacacacacacacac 1620
QY 1621 cctcacctgaaagcagaggttggaaacacacacacacacacacacacacacac 1680
DB 1621 cctcacctgaaagcagaggttggaaacacacacacacacacacacacacacac 1680
QY 1681 ctgagggagatctac 1740
DB 1681 ctgagggagatctac 1740
QY 1741 atctgagatctgcttcaacacacacacacacacacacacacacacacacacac 1800
DB 1741 atctgagatctgcttcaacacacacacacacacacacacacacacacacacac 1800
QY 1801 acaggtgtgtccaggt 1860
DB 1801 acaggtgtgtccaggt 1860
QY 1861 tctgctgt 1920
DB 1861 tctgctgt 1920
QY 1921 ggcattacagtgatcatcatcagaaggtcatcctcgtgagacacacacacacac 1980
DB 1921 ggcattacagtgatcatcatcagaaggtcatcctcgtgagacacacacacacac 1980
QY 1981 atctacttgcttctcttctggtctggttgaagcctgtgagccttgagcagagag 2040
DB 1981 atctacttgcttctcttctggtctggttgaagcctgtgagccttgagcagagag 2040
QY 1978 atctacttgcttctcttctggtctggttgaagcctgtgagccttgagcagagag 2037
DB 1978 atctacttgcttctcttctggtctggttgaagcctgtgagccttgagcagagag 2037

[illegible]

```

FT      /product= "vanilloid receptor-like (VR-L) protein"
FT      /transl_except= (pos: 802..804, aa: Gly)
FT      /transl_except= (pos: 955..957, aa: Lys)
FT      /transl_except= (pos: 2035..2037, aa: Thr)
FT      /transl_except= (pos: 2355..2358, aa: Xaa)
FT      /note= "Xaa is an unspecified amino acid"
PN      WO200022121-A2.
XX      20-APR-2000.
XX      08-OCT-1999; 99WO-GB03348.
XX      09-OCT-1998; 98GB-0022124.
XX      (UNIO ) UNITV COLLEGE LONDON.
PI      Garcia R, Wood JN, England S;
DR      WPI; 2000-317978/27.
DR      P-PSDB; AAY84834.
XX      Novel non-selective cation channel protein and nucleotides useful as
PT      screening agents and in gene therapy of disorders associated with
PT      sensory neurons and leucocytes such as pain, autoimmune disorders and
PT      leukemia
XX      Claim 5; Fig 3A; 55pp; English.
PS      The present sequence encodes a non-selective cation channel protein,
XX      designated vanilloid receptor-like 1 (VR-L). The protein is obtained
XX      from human T lymphocytes. The VR-L protein is activated by noxious heat,
XX      and is not capsaicin sensitive. VR-L is expressed in sensory neurons,
XX      and is likely to play a role in mediating the pain and inflammation
XX      accompanying tissue damage (nociception). The VR-L polynucleotide is
XX      useful for influencing the electrophysiological and/or pharmacological
XX      properties of a cell, and is also useful in the gene therapy treatment
XX      of disorders associated with sensory neurons and/or cells of the immune
XX      system and also for the preparation of a medicament for use in gene
XX      therapy. The VR-L polynucleotides and polypeptides are useful for
XX      identifying a substance with ion-channel modulating activity (such as
XX      analgesics), or compounds which affect nociception, immunomodulatory
XX      agents, neuromodulatory agents.
SQ      Sequence 2765 BP: 560 A; 821 C; 792 G; 589 T; 3 other:

Query Match          96.9%; Score 2720.6; DB 21; Length 2765;
Best Local Similarity 99.2%; Pred. No. 0;
Matches 2743; Conservative 0; Mismatches 22; Indels 1; Gaps 1.

      3 ctatgcctctctgcaagggagatgaagctccgtcttcacacgttcgcggtgcagcgg 62
      1 ctatgcctctctgcaagggagatgaagctccgtcttcacacgttcgcggtgcagcgg 59
      63 tgggctcgaaggtgacacgagagacacgaacctctgtgcctggaagcttagtgcacaagctcg 122
      60 tgggctcgaaggtgacacgagagacacgaacctctgtgcctggaagcttagtgcacaagctcg 119
      123 ggaagggaaggttcgcgcgcctctctgtcgtlcaagcgcgcgcgcgcgccttcgcgcttaactc 182
      120 ggaagggaaggttcgcgcgcctctctgtcgtlcaagcgcgcgcgcgcgccttcgcgcttaactc 179
      183 ctccgcgcagccctctactgagaagctccgcggatccagcagcgcgcgcgcgcctctgcgct 242
      180 ctccgcgcagccctctactgagaagctccgcggatccagcagcgcgcgcgcgcctctgcgct 239
      243 cagctctcgggggtcctcatcgaagcacaacccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 302
      240 cagctctcgggggtcctcatcgaagcacaacccgcgcgcgcgcgcgcgcgcgcgcgcgcgcgcgc 299
      303 ttgaatctccatctgcacagaaggtctctgtctgtagcgcgcgcgcgcgccttcctctctagat 362

```

Db 300 tlgacatctccatctgcacagaggtccctggtctgagccgagcagccctctctctagat 359
Qy 363 gacctaacctccagctctccagttctcaggtctgagacatlgatgagagccaaaga 422
Db 360 gacctaacctccagctctccagttctcaggtctgagacatlgatgagagccaaaga 419
Qy 423 tggctctgagcgagacagagaaagctggaatlttgagagcggtctctccatgagtc 482
Db 420 tggctctgagcgagacagagaaagctggaatlttgagagcggtctctccatgagtc 479
Qy 483 aacgtctccaggggagagacccggaatctgcctccctcagatgaagatcaactcaacccg 542
Db 480 aacgtctccaggggagagacccggaatctgcctccctcagatgaagatcaactcaacccg 539
Qy 543 aaagggaaaggtctcagatcagccagatccaaacccgatttgaccggatctgcctcaaa 602
Db 540 aaagggaaaggtctcagatcagccagatccaaacccgatttgaccggatctgcctcaaa 599
Qy 603 tgcgtctcccggtgtctcccgagatctgctggaatctccagatlaecttgagcaagac 662
Db 600 tgtgtctcccggtgtctcccgagatctgctggaatctccagatlaecttgagcaagac 659
Qy 663 cagcaaggtacctcaacgactcggatcagatcagagggctccacaggtgaagacgtgctgat 722
Db 660 cagcaaggtacctcaacgactcggatcagatcagagggctccacaggtgaagacgtgctgat 719
Qy 723 gaaggtctgtctgaacctgaagacagatcaatgctgctgcatctgcctgtctgagat 782
Db 720 gaaggtctgtctgaacctgaagacagatcaatgctgctgcatctgcctgtctgagat 779
Qy 783 cgaacaggtactctggaatctccagccctgtgtaaatgcccagtgacagatgactatca 842
Db 780 cgaacaggtactctggaatctccagccctgtgtaaatgcccagtgacagatgactatca 839
Qy 843 ccgaagcccaaggtctctcacatctgccaatgtggaagagatctcgaatgtctgagatc 902
Db 840 ccgaagcccaaggtctctcacatctgccaatgtggaagagatctcgaatgtctgagatc 899
Qy 903 cctgtgtggaagtgtggaatctgcatctgcctgcgagcgtctctccaaagag 962
Db 900 cctgtgtggaagtgtggaatctgcatctgcctgcgagcgtctctccaaagatg 959
Qy 963 ccaaggtgactctcttattctcggtgagctaccctctctcttgccgcttgacaaaga 1022
Db 960 ccaaggtgactctcttattctcggtgagctaccctctctcttgccgcttgacaaaga 1019
Qy 1023 gtcggagtgtgtgaagcttactctcttgagaaacccacacagcccgccagcgtgagagccac 1082
Db 1020 gtcggagtgtgtgaagcttactctcttgagaaacccacacagcccgccagcgtgagagccac 1079
Qy 1083 tgaactccaggggcaacacagctcctgtcatctgctagtgatctcgcgacaactcagctga 1142
Db 1080 tgaactccaggggcaacacagctcctgtcatctgctagtgatctcgcgacaactcagctga 1139
Qy 1143 gaaacttgcaactgtgtgacagcatgtatgtggtctcctccaaagctgtgggcccgtctctg 1202
Db 1140 gaaacttgcaactgtgtgacagcatgtatgtggtctcctccaaagctgtgggcccgtctctg 1199
Qy 1203 ccttacgtgtcagacttgaggaacatctcgcaacactgtcaggaatctcaacgctctgaagtgc 1262
Db 1200 ccttacgtgtcagacttgaggaacatctcgcaacactgtcaggaatctcaacgctctgaagtgc 1259
Qy 1263 cgcgaagagagggcaagatctgaatlttctcagggacatctctgcagcggagtcttccagact 1319
Db 1260 cgcgaagagagggcaagatctgaatlttctcagggacatctctgcagcggagtcttccagact 1319
Qy 1323 gggccacacttctccgaaatctcaacgagtggtgctatgggctgtccgggtctgctgtga 1382
Db 1320 gggccacacttctccgaaatctcaacgagtggtgctatgggctgtccgggtctgctgtga 1379
Qy 1383 tgaactgtgtctgtgagagcgtgtgagagaaactcaagtgctgagagataatgtcccttca 1442
Db 1380 tgaactgtgtctgtgagagcgtgtgagagaaactcaagtgctgagagataatgtcccttca 1439

Qy 1443 tlgcaagagcccgcaacggacaacggaaatggctgctlttgagagcccttgaaacaaatgtctga 1502
Db 1440 tlgcaagagcccgcaacggacaacggaaatggctgctlttgagagcccttgaaacaaatgtctga 1499
Qy 1503 ggcgaatgtggatctgtctcatctcccaagtctcttcttaaatctctgtgtatctgata 1562
Db 1500 ggcgaatgtggatctgtctcatctcccaagtctcttcttaaatctctgtgtatctgata 1559
Qy 1563 catgtcatcttcaacgcgctgtgctacatcaagctcagctccttgaaagaagcagccccc 1622
Db 1560 catgtcatcttcaacgcgctgtgctacatcaagctcagctccttgaaagaagcagccccc 1619
Qy 1623 tcaactgaaagcggaggttggaaactcaatgtctgtcagcgggccaatcttactctgtct 1682
Db 1620 tcaactgaaagcggaggttggaaactcaatgtctgtcagcgggccaatcttactctgtct 1679
Qy 1683 aggggggatactactctctctgtggccagctgtgtgatactcttgccggccagtgctcat 1742
Db 1680 aggggggatactactctctctgtggccagctgtgtgatactcttgccggccagtgctcat 1739
Qy 1743 ctggatctcgttcatagacagctacttgaatcctctctctctgtctcagccctgtctcaac 1802
Db 1740 ctggatctcgttcatagacagctacttgaatcctctctctctgtctcagccctgtctcaac 1799
Qy 1803 agtgtgtccaggtgtgtgttctcctgtgccaatgagtgtaactgtccctgtgtgtc 1862
Db 1800 agtgtgtccaggtgtgtgttctcctgtgccaatgagtgtaactgtccctgtgtgtc 1859
Qy 1863 tgcgtgtgtcgggtgtgtgtcgtgaacctgttactatacagtggtctccagcaacag 1922
Db 1860 tgcgtgtgtcgggtgtgtgtcgtgaacctgttactatacagtggtctccagcaacag 1919
Qy 1923 catctacatgtcatatcatccagaagttcaatctctgcggagccctgtctcctctctgat 1982
Db 1920 catctacatgtcatatcatccagaagttcaatctctgcggagccctgtctcctctctgat 1979
Qy 1983 ctactatgtctctcttctctgtcgtctgtgtagccctgtgtgagccttgagccagagagctgt 2042
Db 1980 ctactatgtctctcttctctgtcgtctgtgtagccctgtgtgagccttgagccagagagctgt 2039
Qy 2043 ggcgccccgaagctctctacagggccccaatgcccacagagtgatcgtgagcccatgagagga 2102
Db 2040 ggcgccccgaagctctctacagggccccaatgcccacagagtgatcgtgagcccatgagagga 2099
Qy 2103 ggaagacgaggggcaacggggccagatcagaggtatcctctggaagcctctctgagactct 2162
Db 2100 ggaagacgaggggcaacggggccagatcagaggtatcctctggaagcctctctgagactct 2159
Qy 2163 caaatcacaatctgagcatgtggcgagctgtcctccagagcagctgcaactctccggcat 2222
Db 2160 caaatcacaatctgagcatgtggcgagctgtcctccagagcagctgcaactctccggcat 2219
Qy 2223 ggtgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgt 2282
Db 2220 ggtgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgtcgt 2279
Qy 2283 catcgcctcctcagagaggaacccgtcaacagctgtcgccaatgcaagcttgagatctgga 2342
Db 2280 catcgcctcctcagagaggaacccgtcaacagctgtcgccaatgcaagcttgagatctgga 2339
Qy 2343 gctgcagaaagcactctgtccttgagagatggaatgtctatgtgtgtgagagaaaga 2402
Db 2340 gctgcagaaagcactctgtccttgagagatggaatgtctatgtgtgtgagagaaaga 2399
Qy 2403 gcaagcggagaggtgtgagatgtgacagcttgagcaataagccagatgagccggatgagag 2462
Db 2400 gcaagcggagaggtgtgagatgtgacagcttgagcaataagccagatgagccggatgagag 2459
Qy 2463 ctgtgtactcagaggtgagagaggtgaactgggcttcaatgtggagcagagcctgcaagct 2522
Db 2460 ctgtgtactcagaggtgagagaggtgaactgggcttcaatgtggagcagagcctgcaagct 2519

QY	2523	gtgagagagaccctgcagagggcaggtgtctcctcgaaactctcagaaacctgtctcgtcttc	2582
Db	2520	gtctgagagaccctgcagagggcaggtgtctcctcgaaactctcagaaacctgtctcgtcttc	2579
QY	2583	ccccccaaagagatgagatgtgtccctctgagaaacctgtgtccgcttcagactcct	2642
Db	2580	ccccccaaagagatgagatgtgtccctctgagaaacctgtgtccgcttcagactcct	2639
QY	2643	ccagttccaactgtatgtgcccagatgcagcagagagccagagagacagagatcttc	2702
Db	2640	ccagttccaactgtatgtgcccagatgcagcagagagccagagagacagagatcttc	2699
QY	2703	caaccacaactgtctgtcgtctctgtgggtcccaatgtaatctgtgtgcaatatattttac	2762
Db	2700	caaccacaactgtctgtcgtctctgtgggtcccaatgtaatctgtgtgcaatatattttac	2759
QY	2763	taactc 2768	
Db	2760	taactc 2765	
RESULT	4		
AAVS9691			
ID	AAVS9691	standard; DNA; 2779 BP.	
XX			
AC	AAVS9691;		
XX			
DT	19-JAN-1999	(first entry)	
XX			
DE	Human secreted protein gene 181 clone HAFNU18.		
XX			
KW	Human; secreted protein; fusion protein; gene therapy; protein therapy;		
KW	diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;		
KW	developmental abnormality; foetal deficiency; blood; allergy; renal; ds;		
KW	immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;		
KW	inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;		
KW	cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;		
KW	osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;		
KW	endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.		
XX			
OS	Homo sapiens.		
XX			
PN	W09839448-A2.		
XX			
PD	11-SEP-1998.		
XX			
PE	06-MAR-1998;	98MO-US04493.	
XX			
PR	02-OCT-1997;	97US-0061060.	
PR	07-MAR-1997;	97US-0038621.	
PR	07-MAR-1997;	97US-0040161.	
PR	07-MAR-1997;	97US-0040162.	
PR	07-MAR-1997;	97US-0040163.	
PR	07-MAR-1997;	97US-0040353.	
PR	07-MAR-1997;	97US-0040336.	
PR	07-MAR-1997;	97US-0040626.	
PR	11-APR-1997;	97US-0043311.	
PR	11-APR-1997;	97US-0043312.	
PR	11-APR-1997;	97US-0043313.	
PR	11-APR-1997;	97US-0043314.	
PR	11-APR-1997;	97US-0043568.	
PR	11-APR-1997;	97US-0043569.	
PR	11-APR-1997;	97US-0043576.	
PR	11-APR-1997;	97US-0043578.	
PR	11-APR-1997;	97US-0043580.	
PR	11-APR-1997;	97US-0043580.	
PR	11-APR-1997;	97US-0043670.	
PR	11-APR-1997;	97US-0043671.	
PR	11-APR-1997;	97US-0043672.	
PR	11-APR-1997;	97US-0043674.	
PR	23-MAY-1997;	97US-0047492.	
PR	23-MAY-1997;	97US-0047500.	

PR	23-MAY-1997	97US-0047501
PR	23-MAY-1997	97US-0047502
PR	23-MAY-1997	97US-0047503
PR	23-MAY-1997	97US-0047581
PR	23-MAY-1997	97US-0047582
PR	23-MAY-1997	97US-0047583
PR	23-MAY-1997	97US-0047584
PR	23-MAY-1997	97US-0047585
PR	23-MAY-1997	97US-0047586
PR	23-MAY-1997	97US-0047587
PR	23-MAY-1997	97US-0047588
PR	23-MAY-1997	97US-0047589
PR	23-MAY-1997	97US-0047590
PR	23-MAY-1997	97US-0047592
PR	23-MAY-1997	97US-0047593
PR	23-MAY-1997	97US-0047594
PR	23-MAY-1997	97US-0047595
PR	23-MAY-1997	97US-0047601
PR	23-MAY-1997	97US-0047612
PR	23-MAY-1997	97US-0047613
PR	23-MAY-1997	97US-0047614
PR	23-MAY-1997	97US-0047615
PR	23-MAY-1997	97US-0047650
PR	23-MAY-1997	97US-0047617
PR	23-MAY-1997	97US-0047618
PR	23-MAY-1997	97US-0047632
PR	23-MAY-1997	97US-0047633
PR	23-MAY-1997	97US-0047634
PR	06-JUN-1997	97US-0048364
PR	06-JUN-1997	97US-0048670
PR	13-JUN-1997	97US-0049610
PR	08-JUL-1997	97US-0051326
PR	16-JUL-1997	97US-0052874
PR	18-AUG-1997	97US-0057124
PR	22-AUG-1997	97US-0056630
PR	22-AUG-1997	97US-0056631
PR	22-AUG-1997	97US-0056632
PR	22-AUG-1997	97US-0056633
PR	22-AUG-1997	97US-0056636
PR	22-AUG-1997	97US-0056637
PR	22-AUG-1997	97US-0056642
PR	22-AUG-1997	97US-0056644
PR	22-AUG-1997	97US-0056645
PR	22-AUG-1997	97US-0056646
PR	22-AUG-1997	97US-0056647
PR	22-AUG-1997	97US-0056677
PR	22-AUG-1997	97US-0056878
PR	22-AUG-1997	97US-0056879
PR	22-AUG-1997	97US-0056880
PR	22-AUG-1997	97US-0056881
PR	22-AUG-1997	97US-0056882
PR	22-AUG-1997	97US-0056883
PR	22-AUG-1997	97US-0056884
PR	22-AUG-1997	97US-0056885
PR	22-AUG-1997	97US-0056886
PR	22-AUG-1997	97US-0056887
PR	22-AUG-1997	97US-0056888
PR	22-AUG-1997	97US-0056889
PR	22-AUG-1997	97US-0056903
PR	22-AUG-1997	97US-0056904
PR	22-AUG-1997	97US-0056905
PR	22-AUG-1997	97US-0056906
PR	22-AUG-1997	97US-0056907
PR	22-AUG-1997	97US-0056908
PR	22-AUG-1997	97US-0056909
PR	22-AUG-1997	97US-0056910
PR	22-AUG-1997	97US-0056911
PR	05-SEP-1997	97US-0057650
PR	05-SEP-1997	97US-0057659
PR	05-SEP-1997	97US-0057761

PR 12-SEP-1997; 97US-0058785.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Bednarek DP, Brewer LA, Carter KC, Duan R, Ehnert R, Endress GA,
PI Fieg P, Fertile AM, Fischer CL, Florence KA, Greene JM, Hu JS,
PI K'ang H, Lallier DW, Li Y, Moore PA, Ni J, Olsen HS, Rosen CA,
PI Ruben SM, Shi Y, Soppet DR, Young PE, Yu GL, Zeng Z,
XX
XX WPI; 1998-506364/43.
DR P-PSDB; AAMW4908.

PT New Isolated human genes and the secreted polypeptide(s) they encoded
PT - useful for diagnosis and treatment of e.g. cancers, neurological
PT disorders, immune diseases, inflammation or blood disorders
XX
PS Claim 1, Page 420-421; 721pp: English.

PS Claim 1; Page 420-421; 721pp; English.

CC This sequence represents a nucleic acid molecule designated gene 181
CC from the human cDNA clone HAFN18 (deposited as clone ATCC 97904 and
CC ATCC 209050) which encodes a secreted human protein. The gene can be
CC used to generate fusion proteins by linking to the gene to a human
CC immunoglobulin Fc portion (e.g., AAV59502) for increasing the stability of
CC the fused protein as compared to the human protein only.
CC The invention relates to 186 novel genes and their fragments (nucleic
CC acid sequences: AAV59511-V59812; amino acid sequences AAW4731-W75026)
CC which are useful for preventing, treating or ameliorating medical
CC conditions e.g. by protein or gene therapy. Also, pathological
CC conditions can be diagnosed by determining the amount of the new
CC polypeptides in a sample or by determining the presence of mutations in
CC the new polynucleotides. Specific uses are described for each of the 186
CC polynucleotides, based on which tissues they are most highly expressed in
CC (see AAV59511 for described uses).

SQ Sequence 2779 BP; 600 A; 806 C; 790 G; 569 T; 14 other;

Query Match	92.78	Score 2604.8	DB 19	Length 2779
Best Local Similarity	96.98	Pred. NO. 0		
Matches 72/1, Conservative	11	Mismatches	6	Indels 71
				Gaps 5

QY	1	ggcagagcctgcctcgcgaacagagggaaagtaagctctccggtctctccacccgtgcgcgcgtgcga	60
Db	37	ggctaaagcctgcctcgcgaacagagggaaagtaagctctccggtctctccacccgtgcgcgcgtgcga	96
QY	61	ggctgcctcgaagggcgacccgaagagaccagaacctctgcctgcggagcttaagctgcacagact	120
Db	97	ggctgcctcgaagggcgacccgaagagaccagaacctctgcctgcggagcttaagctgcacagact	156
QY	121	ggggagaggaaggtctccgcgcgcgtctctctctcgtctcagcgcgcgcgcagccctctccgccttcaact	180
Db	157	ggggagaggaaggtctccgcgcgcgtctctctctcgtctcagcgcgcgcgcagccctctccgccttcaact	216
QY	181	tcctcccccgaacccctctcactatctgaagagctccgcgagatccacagacccgcgcgcgcctctgcgc	240
Db	217	tcctcccccgaacccctctcactatctgaagagctccgcgagatccacagacccgcgcgcgcctctgcgc	276
QY	241	ctcagcctgcgcgcgtctcccaagtctcaagtcacaacacccgcgcgcgcgcgcctgcggagagagacagagac	300
Db	277	ctcagcctgcgcgcgtctcccaagtctcaagtcacaacacccgcgcgcgcgcgcctgcggagagagacagagac	335
QY	301	ccttgaaactctcaactctcgaacacagaggtcctcgtgcctgcgaacccgaagcactctctctctctagag	360
Db	336	ccttgaaactctcaactctcgaacacagaggtcctcgtgcctgcgaacccgaagcactctctctctctagag	395
QY	361	atgacactcaacccctccagcctctccacgcttttcaggtcttgagacatctagaatgagagccagaagaa	420
Db	396	atgacactcaacccctccagcctctccacgcttttcaggtcttgagacatctagaatgagagccagaagaa	455
QY	421	gattgcgtctctgaagcgcgcgaacagagaagaagctctgatttttgagacgcgcgtcctcccatggag	480
Db	456	gattgcgtctctgaagcgcgcgaacagagaagaagctctgatttttgagacgcgcgtcctcccatggag	515

[illegible]

[illegible]

Query Match	87.7%	Score 2462.2	DB 22	Length 2469
Best Local Similarity	99.9%	Pred. No. 0		
Matches 2464	Conservative 0	Mismatches 3	Indels 0	Gaps 0
QY	267	caaacccgacgcagcgcgtcgggaggaagacagaccccttgacatctccatctgacagagg	326	
DB	3	cgaagccgacgcagcgcgtcgggaggaagacagaccccttgacatctccatctgacagagg	62	
QY	327	tccttgctgagacgcagcgcgcctccctccctctagagtagactaacctccagctccagct	386	
DB	63	tccttgctgagacgcagcgcgcctccctccctctagagtagactaacctccagctccagct	122	
QY	387	ttccaggttgagacattagatgagagcccaagaatggtctctgagcgcgacagaga	446	

D	b	123	tttcaggttvgagacattaaatvgagagccaaagaaagtgtctctgaggtcgagacaagagga	182
Q	y	447	gcctggaatttvgagagcggtgtctccctccatggaatcacagttccaaaggtcgagacaggaa	506
D	b	183	gctggaattttvgagagcggtgtctccctccatggaatcacagttccaaaggtcgagacaggaa	242
Q	y	507	attgcgcccctcaagataagaaatcaaacctcaactccgaaagggaaacaggtgacagatcaccc	566
D	b	243	attgcgcccctcaagataagaaatcaaacctcaactccgaaagggaaacaggtgacagatcaccc	302
Q	y	567	ggaatccaaacgggaatttgaaccggagatcggtgtctctcaatgtgagttctccgggggtgtcccca	626
D	b	303	ggaatccaaacgggaatttgaaccggagatcggtgtctctcaatgtgagttctccgggggtgtcccca	362
Q	y	627	ggatctgtgtcggaacttccaaagataacttgagacaaagacaaagataacttccaaactcgga	686
D	b	363	ggatctgtgtcggaacttccaaagataacttgagacaaagacaaagataacttccaaactcgga	422
Q	y	687	atacaacagagaggtcccaacaaagataagacgtgtccctgataagaaaggtgtgtctgaaccttaagaa	746
D	b	423	atacaacagagaggtcccaacaaagataagacgtgtccctgataagaaaggtgtgtctgaaccttaagaa	482
Q	y	747	cgagagttcaatgagctcggaatttctgcgaactgtgtcgagatcgacaagaggaactctgagcaattccca	806
D	b	483	cgagagttcaatgagctcggaatttctgcgaactgtgtcgagatcgacaagaggaactctgagcaattccca	542
Q	y	807	ggcccctgtgaataatgcccagatcgacagagatagtacttatccgaagccacaagaggtgtcgat	866
D	b	543	ggcccctgtgaataatgcccagatcgacagagatagtacttatccgaaggtcgatcgatcgat	602
Q	y	867	cgccaatgtgaagaaagagagctctgcagatgtgtgtgaagatccctgtgtgaagaaatgggccaatgt	926
D	b	603	cgccaatgtgaagaaagagagctctgcagatgtgtgtgaagatccctgtgtgaagaaatgggccaatgt	662
Q	y	927	gcatgagccggagccgtcgagccgtgtctctccaaagagggccaaagggagactgtttattctgg	986
D	b	663	gcatgagccggagccgtcgagccgtgtctctccaaagagggccaaagggagactgtttattctgg	722
Q	y	987	tgaagctaacccctctcttttggccgctgtgacacaagacagatggagaaatgtgtgaagatctacctct	1046
D	b	723	tgaagctaacccctctcttttggccgctgtgacacaagacagatggagaaatgtgtgaagatctacctct	782
Q	y	1047	ggagaaacccacaacaaagcccgacagcccttgagagagcaatgtgacttccaaaggggcaacaagttct	1106
D	b	783	ggagaaacccacaacaaagcccgacagcccttgagagagcaatgtgacttccaaaggggcaacaagttct	842
Q	y	1107	gcatgagccctatgtatgtatctccgaaacaactaagctatgataagaaatcttgacatgtgtgaaccagat	1166
D	b	843	gcatgagccctatgtatgtatctccgaaacaactaagctatgataagaaatcttgacatgtgtgaaccagat	902
Q	y	1167	gtatgataaggggtctctccaaagcttggggccggtctctgtccctaacgggtgacgtttgaagat	1226
D	b	903	gtatgataaggggtctctccaaagcttggggccggtctctgtccctaacgggtgacgtttgaagat	962
Q	y	1227	ccgacaaccttcgaagatacttcacagccctctggaagctgtggccgacaaagggggggaagaatctgagat	1286
D	b	963	ccgacaaccttcgaagatacttcacagccctctggaagctgtggccgacaaagggggggaagaatctgagat	1022
Q	y	1287	tttcagagacacatccctcagacgaggattttccaaagatctgaaccacttcccgaaagtctac	1346
D	b	1023	tttcagagacacatccctcagacgaggattttccaaagatctgaaccacttcccgaaagtctac	1082
Q	y	1347	cgaaatgtgtataagggctctccgggtgtccgctgtgataagaccgggttctctgtgagaaagtgt	1406
D	b	1083	cgaaatgtgtataagggctctccgggtgtccgctgtgataagaccgggttctctgtgagaaagtgt	1142
Q	y	1407	tgaagagaaactcagttctgtgagaaatcaatgtcccttcaatcttgacaagagcccgacaacgggacag	1466
D	b	1143	tgaagagaaactcagttctgtgagaaatcaatgtcccttcaatcttgacaagagcccgacaacgggacag	1202
Q	y	1467	aatgtgtcgttttvgagagccctctgaacaactgtctgacagcgaaatvggagatctgtctacatcc	1526
D	b	1203	aatgtgtcgttttvgagagccctctgaacaactgtctgacagcgaaatvggagatctgtctacatcc	1262

QY	157	caagctcctcttaaaactctctgtgtatctgatactacaatgttcaatcttcaaccgctgttc	1586
Db	1263	caagctctctcttaaaactctctgtgtatctgatactacaatgttcaatcttcaaccgctgttc	1322
QY	1587	ctaccatcaagccttaaccctcttgagaagaagacgcccctcaaccctgaaagcggaatttgaaa	1646
Db	1323	ctaccatcaagccttaaccctcttgagaagaagacgcccctcaaccctgaaagcggaatttgaaa	1382
QY	1647	ctccatgctgctgaacgagcacatctcatctctgatagggggagatactactctgttgg	1706
Db	1383	ctccatgctgctgaacgagcacatctcatctctgatagggggagatactactactctctgttgg	1442
QY	1707	ccaagctgtgtactctgctggggcgccaagtggttcaatcttgatctctgtttcatagaagata	1766
Db	1443	ccaagctgtgtgtactctgctggggcgccaagtggttcaatcttgatctctgtttcatagaagata	1502
QY	1767	cttggaaatactctctctctgtctccagaagccctgtctcaacagctggtctccaaagtgtgtt	1826
Db	1503	cttggaaatactctctctctgtctccagaagccctgtctcaacagagctggtctccaaagtgtt	1682
QY	1827	ccctggccaatcgagtggtactccctgtccctgtgtgtctgctgctgtgtgtgtgtgtgtgt	1886
Db	1553	ccctggccaatcgagtggtactccctgtccctgtgtgtgtctgctgctgtgtgtgtgtgtgt	1622
QY	1887	ccctgttactataatacaagctgtctccagaacacacagacatctcaatgtgtcatatccaaga	1946
Db	1623	ccctgttactataatacaagctgtctccagaacacacagacatctcaatgtgtcatatccaaga	1682
QY	1947	ggtcatccctgctgggaacctgtgcgtcttccctctgatactactagtctctctcttcgctt	2006
Db	1683	ggtcatccctgctgggaacctgtgcgtcttccctctgatactactagtctctctcttcgctt	1742
QY	2007	cgctgtatgacctgttgagacctctgaccagaagagctgtggcccccgaagctccctacaagccc	2066
Db	1743	cgctgtatgacctgtgtgagacctctgaccagaagagctgtggcccccgaagctctctacaagccc	1802
QY	2067	caatgtccacaagatcagttgcagcccatagtgaggggacagagagcgaagccaacggggccca	2126
Db	1803	caatgtccacaagagatcagttgcagcccatagtgaggggacagagagcgaagccaacggggccca	1862
QY	2127	gttaagaagggtatctctgtgaaagccctctctgtgaagctcttcaaatctcaacatctcgacatggga	2186
Db	1863	gttaagaagggtatctctgtgaaagccctctctgtgaagctcttcaaatctcaacatctcgacatggga	1922
QY	2187	gctctgacctccacaagagagagctgtcaactctccgcgacatgtgctgctgcctgcctgcctca	2246
Db	1923	gctctgacctccacaagagagagctgtcaactctccgcgacatgtgctgctgcctgcctgcctca	1982
QY	2247	cgctgctgctcaactcaatctctgtctcaacaatgtctcatctgcgcccctcatagagcggaacct	2306
Db	1983	cgctgctgctcaactcaatctctgtctcaacaatgtctcatctgcgcccctcatagagcggaacct	2042
QY	2307	caaacagctgtccgaactgtgaacagctgtgggatactctggaaagctgtgaaagacacatctcttct	2366
Db	2043	caaacagctgtctgcaactgtgaacagctgtgggatactctggaaagctgtgaaagacacatctcttct	2102
QY	2367	ggagataggagaaatgtgctatgtgtgtgtgcagagaaagacagcgggcaggtgtgtatgtgtac	2426
Db	2103	ggagataggagaaatgtgctatgtgtgtgtgtgcagagaaagacagcgggcaggtgtgtatgtgtac	2162
QY	2427	cgtttggacaataaacagagatgtgacggcccggaataagcgctgtgtgtcttcaaggtgtggaggaagt	2486
Db	2163	cgtttggacaataaacagagatgtgacggcccggaataagcgctgtgtgtgtcttcaaggtgtggaggaagt	2222
QY	2487	gaactgtgacct	2546
Db	2223	gaactgtgacct	2282
QY	2547	tgctccctcgaaactctctcgaaacctgtctctgtctccctctcccaaggagatgaaagtgtg	2606
Db	2283	tgctccctcgaaactctctcgaaacctgtctctgtctccctctcccaaggagatgaaagtgtg	2342

OY 2607 tgcctcagagaaactatgtgccgctcagctctccagctccagctgaatgagccagatg 2666
|||||
Db 2343 tgcctcagagaaactatgtgccgctcagctctccagctccagctgaatgagccagatg 2402
OY 2667 cagcagagagccagagacagagagagatcttcacacactctctgagctctggg 2726
|||||
Db 2403 cagcagagagccagagacagagagagatcttcacacactctgagctctggg 2462
OY 2727 tcccaagt 2733
|||||
Db 2463 tcccaagt 2469

RESULT 6
AAV59807
ID AAV59807 standard; DNA; 2860 BP.
XX
AC AAV59807;
XX
DT 19-JAN-1999 (first entry)
XX
DE Human secreted protein gene 181 clone HAFU18.
XX
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
XX
OS Homo sapiens.
XX
PN WC9839448-A2.
PD 11-SEP-1998.
XX
PF 06-MAR-1998; 98WO-US04493.
XX
PR 02-OCT-1997; 97US-0061060.
PR 07-MAR-1997; 97US-0038621.
PR 07-MAR-1997; 97US-0040161.
PR 07-MAR-1997; 97US-0040162.
PR 07-MAR-1997; 97US-0040163.
PR 07-MAR-1997; 97US-0040333.
PR 07-MAR-1997; 97US-0040334.
PR 07-MAR-1997; 97US-0040336.
PR 07-MAR-1997; 97US-0040626.
PR 11-APR-1997; 97US-0043311.
PR 11-APR-1997; 97US-0043312.
PR 11-APR-1997; 97US-0043313.
PR 11-APR-1997; 97US-0043314.
PR 11-APR-1997; 97US-0043358.
PR 11-APR-1997; 97US-0043569.
PR 11-APR-1997; 97US-0043576.
PR 11-APR-1997; 97US-0043578.
PR 11-APR-1997; 97US-0043580.
PR 11-APR-1997; 97US-0043588.
PR 11-APR-1997; 97US-0043659.
PR 11-APR-1997; 97US-0043670.
PR 11-APR-1997; 97US-0043671.
PR 11-APR-1997; 97US-0043672.
PR 11-APR-1997; 97US-0043674.
PR 23-MAY-1997; 97US-0047492.
PR 23-MAY-1997; 97US-0047500.
PR 23-MAY-1997; 97US-0047501.
PR 23-MAY-1997; 97US-0047502.
PR 23-MAY-1997; 97US-0047503.
PR 23-MAY-1997; 97US-0047581.
PR 23-MAY-1997; 97US-0047582.
PR 23-MAY-1997; 97US-0047583.
PR 23-MAY-1997; 97US-0047584.
PR 23-MAY-1997; 97US-0047585.

PR 23-MAY-1997; 97US-0047586.
PR 23-MAY-1997; 97US-0047587.
PR 23-MAY-1997; 97US-0047588.
PR 23-MAY-1997; 97US-0047589.
PR 23-MAY-1997; 97US-0047590.
PR 23-MAY-1997; 97US-0047592.
PR 23-MAY-1997; 97US-0047593.
PR 23-MAY-1997; 97US-0047594.
PR 23-MAY-1997; 97US-0047595.
PR 23-MAY-1997; 97US-0047596.
PR 23-MAY-1997; 97US-0047597.
PR 23-MAY-1997; 97US-0047598.
PR 23-MAY-1997; 97US-0047599.
PR 23-MAY-1997; 97US-0047600.
PR 23-MAY-1997; 97US-0047601.
PR 23-MAY-1997; 97US-0047612.
PR 23-MAY-1997; 97US-0047613.
PR 23-MAY-1997; 97US-0047614.
PR 23-MAY-1997; 97US-0047615.
PR 23-MAY-1997; 97US-0047617.
PR 23-MAY-1997; 97US-0047618.
PR 23-MAY-1997; 97US-0047632.
PR 23-MAY-1997; 97US-0047633.
PR 06-JUN-1997; 97US-0048964.
PR 06-JUN-1997; 97US-0048974.
PR 13-JUN-1997; 97US-0049610.
PR 08-JUL-1997; 97US-0051926.
PR 16-JUL-1997; 97US-0052874.
PR 16-AUG-1997; 97US-0055724.
PR 22-AUG-1997; 97US-0056610.
PR 22-AUG-1997; 97US-0056631.
PR 22-AUG-1997; 97US-0056632.
PR 22-AUG-1997; 97US-0056636.
PR 22-AUG-1997; 97US-0056637.
PR 22-AUG-1997; 97US-0056662.
PR 22-AUG-1997; 97US-0056664.
PR 22-AUG-1997; 97US-0056845.
PR 22-AUG-1997; 97US-0056862.
PR 22-AUG-1997; 97US-0056864.
PR 22-AUG-1997; 97US-0056872.
PR 22-AUG-1997; 97US-0056874.
PR 22-AUG-1997; 97US-0056875.
PR 22-AUG-1997; 97US-0056876.
PR 22-AUG-1997; 97US-0056877.
PR 22-AUG-1997; 97US-0056878.
PR 22-AUG-1997; 97US-0056879.
PR 22-AUG-1997; 97US-0056880.
PR 22-AUG-1997; 97US-0056881.
PR 22-AUG-1997; 97US-0056882.
PR 22-AUG-1997; 97US-0056884.
PR 22-AUG-1997; 97US-0056886.
PR 22-AUG-1997; 97US-0056887.
PR 22-AUG-1997; 97US-0056888.
PR 22-AUG-1997; 97US-0056889.
PR 22-AUG-1997; 97US-0056892.
PR 22-AUG-1997; 97US-0056893.
PR 22-AUG-1997; 97US-0056894.
PR 22-AUG-1997; 97US-0056903.
PR 22-AUG-1997; 97US-0056908.
PR 22-AUG-1997; 97US-0056909.
PR 22-AUG-1997; 97US-0056910.
PR 22-AUG-1997; 97US-0056911.
PR 05-SEP-1997; 97US-0057650.
PR 05-SEP-1997; 97US-0057669.
PR 05-SEP-1997; 97US-0057761.
PR 12-SEP-1997; 97US-0058785.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Beharlik DP, Brewer LA, Carter KC, Duan R, Ebner R, Endress GA,
PI Feng P, Ferrite AM, Fischer CL, Florence KA, Greene JM, Hu JS,
PI Kyaw H, Lafleur DM, Li Y, Moore PA, Ni J, Olsen HS, Rosen CA,
PI Ruben SM, Shi Y, Soppet DR, Young PE, Yu GL, Zeng Z;


```
Db 1737 cctatccctgtaggggagctacccctcgtgaggcagctgtagctctcgcgc 1796
1730 gccacgtgtcatctgagctcgtctcatagacagctactct-gaatcctctcctgttc 1788
1797 gccacgtgtcatctgagctcgtctcatagacagctactctggaatccctcctcgttc 1856
1789 caggccctgc-tcacagtgtgtctccaggtgctgttctct-ggccaatcagtgctacc 1846
1857 caggccctgctcacaggtgtgtccaggtgtgtgttctcctggccaatcagtgctacc 1916
1847 tgcctcgtctgtctgctgctgtgt-gctggctgtgctgtaacctgtactt-atacag 1904
1917 tgcctcgtctgtctgctgctgtgtgctgctgctgtaacctgtacttataacag 1976
1905 tggc-ttcacagacacagagctacaggtgcataatccaaaggtactcctgaggacc 1963
1977 tggcgtctccacacacagc----- 1996
1964 tgcctcgtctcctctgatactactagctctcctcttcgtcgtctgtagcctgtga 2023
1997 -----agctacagtttcatgttcctctgaagcctctgtga 2031
2024 gctctgagccagagagcttgccgcgccgaagctcctacagcccaatgccaagatcag 2083
2032 gctctgagccagagagcttgccgcgccgaagctcctacagcccaatgccaagatcag 2091
2084 tgcagcccatgaggagagagagagagagagagagagagagagagagagagagagag 2143
2092 tgcagcccatgaggagagagagagagagagagagagagagagagagagagagagag 2151
2144 aagcctcctctggaagctctcaaatcaacacacagcatgagagagagagagagagag 2203
2152 aagcctcctctggaagctctcaaatcaacacagcatgagagagagagagagagagag 2211
2204 agctgcacctcgcgcgaatggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2263
2212 agctgcacctcgcgcgaatggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2271
2264 tctcgtcgtcaaatgctacatgcgcgcctcctacagagagagagagagagagagag 2323
2272 tctcgtcgtcaaatgctacatgcgcgcctcctacagagagagagagagagagagag 2329
2324 acagctggaagcatctggaagctgagaaagcactctgtcctctggaagatgagatgct 2383
2330 acagctggaagcatctggaagctgagaaagcactctgtcctctggaagatgagatgct 2389
2384 atgtgtgtgtgagagagagagagagagagagagagagagagagagagagagagag 2442
2390 atgtgtgtgtgagagagagagagagagagagagagagagagagagagagagagag 2449
2443 gatggcagcccgagatgagcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2501
2450 gatggcagcccgagatgagcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2509
2502 ggaagcagagagctgtcctacgtctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2561
2510 ggaagcagagagctgtcctacgtctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2569
2562 cgaagaacctgtcctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2621
2570 cgaagaacctgtcctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2629
2622 ctatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2681
2630 ctatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2689
2682 ggaagcagagagagagagagagagagagagagagagagagagagagagagagagag 2741
2690 ggaagcagagagagagagagagagagagagagagagagagagagagagagagagag 2749
2742 gtggcaaatatataatttctactaactcaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa 2799
|||||
```

```
Db 2750 gtggcaaatatataatttctactaactcaaaaaaaaaaaaaaaaaaaaaaaaaa 2807
RESULT 7
AAx87492
ID AAx87492 standard; cDNA; 2380 BP.
XX
XX AAx87492;
AC
XX
XX 08-Oct-1999 (first entry)
DT
XX
DE Human vanilloid receptor-related polypeptide 1 (VRRP-1) cDNA.
XX
XX Vanilloid receptor-related polypeptide 1; VRRP-1; VR2;
XX
XX capsaicin receptor; VR1; human; vanilloid; analgesic; pain;
XX
XX inflammation; therapy; diagnosis; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 19..2316
XX FT /*tag= a
XX
XX MO9937675-A1.
XX
XX 29-JUL-1999.
XX
XX 22-JAN-1999; 99WO-US01418.
XX
XX 22-JAN-1998; 98US-0072151.
XX
XX (REGC ) UNIV CALIFORNIA.
XX
XX Brake AJ, Caterina M, Julius DJ;
XX
XX WP1: 1999-469113/39.
XX
XX P-PSDB; AAY06559.
XX
XX New isolated capsaicin receptor polypeptide and related nucleic acid
XX PT - useful for detecting vanilloid compounds, identifying modulators,
XX and in diagnosis or treatment of e.g. pain and inflammation
XX
XX Claim 8; Page 107-110; 120pp; English.
XX
XX PS
XX
XX This is the nucleotide sequence of cDNA coding for human vanilloid
XX CC receptor-related polypeptide 1 (VRRP-1 or VR2). The cDNA was
XX CC isolated from a CCR-CEM cell cDNA. VRRP-1 (AAY06559) is an example
XX CC of a capsaicin receptor-related polypeptide of the invention. It
XX CC is not activated by capsaicin or heat, but may interact with the
XX CC novel capsaicin receptor VR1 (see AAY06558). The invention provides
XX CC vanilloid receptor polypeptides and polynucleotides, including
XX CC capsaicin receptor-related polypeptides and polynucleotides, as well
XX CC as expression vectors, host cells and transgenic animals. It also
XX CC provides a method of using such receptors to identify vanilloid
XX CC compounds in natural products or to screen candidate compounds that
XX CC modulate capsaicin receptor function for use as analgesics (vanilloid
XX CC analogues, therapeutic antibodies, antisense oligonucleotides,
XX CC capsaicin receptor-encoding polynucleotides for gene therapy),
XX CC flavour-enhancing agents, etc. Capsaicin receptor-related
XX CC polypeptides and specific antibodies can also be used for the
XX CC diagnosis and treatment of human disease and pain. Polynucleotides
XX CC can be used as probes to determine the structure, function, location
XX CC and expression of capsaicin receptor, receptor subtypes and capsaicin
XX CC receptor-related polypeptides in mammals (including humans) and to
XX CC investigate associations between disease states or clinical disorders
XX CC (particularly those involving acute and chronic pain or inflammation)
XX CC and defects or alterations in receptor structure, expression or
XX CC function.
XX
XX Sequence 2380 BP; 491 A; 698 C; 678 G; 513 T; 0 other;
```

Query Match

84.7%; Score 2378.4; DB 20; Length 2380;

QY 2503 gagcagacgctgcttaagctgtgtgagaccgctcaaggagcaggtgtccctcgaacttc 2562
|||||
Db 2161 gagagagcgcgtccttaagctgtgtgagaccgctcaaggagcaggtgtccctcgaacttc 2220
QY 2563 gagaacctgtctgtgcttccctcccaaggagatgagatgtgctctgaagaaac 2622
|||||
Db 2221 gagaaacctgtctgtgcttccctcccaaggagatgagatgtgctctgaagaaac 2280
QY 2623 tatgtccctcgaagctcctcgaatcgaatgagtcgagcccaatgacagagagccagag 2682
|||||
Db 2281 tatgtccctcgaagctcctcgaatcgaatgagtcgagcccaatgacagagagccagag 2340
QY 2683 gacagagcagagatcttcccaacacatctgctgctct 2722
|||||
Db 2341 gacagagcagagatcttcccaacacatctgctgctct 2380

RESULT 8
AAZ07114
ID AAZ07114 standard; cDNA; 2351 BP.
XX
AC AAZ07114;
XX
08-OCT-1999 (first entry)
XX
Human vanilloid receptor homologue VANILREP2 encoding cDNA.
XX
Human: vanilloid receptor homologue; VANILREP2; polymorphic variant;
KW PVP-1; therapy; diagnosis; chronic pain; neuropathic; postoperative;
KW rheumatoid arthritis; neuralgia; algesia; nerve injury; ischaemia;
KW neurodegeneration; stroke; incontinence; inflammatory disorder; ss.
XX
OS Homo sapiens.
XX
XX Location/Qualifiers
FT CDS 5..2299
FT /tag- a
FT /product- "VANILREP2"
FT /note- "vanilloid receptor homologue"
XX
PN WO937765-A1.
XX
PD 29-JUL-1999.
XX
PF 25-JAN-1999; 99MO-EP00420.
XX
PR 20-JAN-1999; 99GB-0001209.
PR 27-JAN-1998; 98EP-0300549.
PR 26-OCT-1998; 98GB-0023421.
XX
PA (SMIK) SMITHKLINE BEECHAM PLC.
XX
PI Davis JB, Duckworth DM, Hayes PD;
XX
DR WPI; 1999-479049/40.
XX
DR P-PSDB; AAY29469.
XX
PT New human vanilloid receptor homologues (VANILREP2)
XX
XX
XX
PS Claim 9; Page 29-30; 47pp; English.
XX
CC The present sequence encodes a human vanilloid receptor homologue,
CC designated VANILREP2. VANILREP2 can be used to diagnose disease or
CC susceptibility to disease related to expression or activity of
CC VANILREP2 polypeptides. VANILREP2 may be used to treat diseases
CC including pain, (for example chronic, neuropathic, postoperative,
CC rheumatoid arthritis), neuralgia, algesia, nerve injury, ischaemia,
CC neurodegeneration, stroke, incontinence, and inflammatory disorders.
XX
SQ Sequence 2351 BP; 486 A; 684 C; 676 G; 505 T; 0 other;

Query Match 83.6%; Score 2347.8; DB 20; Length 2351;
Best Local Similarity 99.9%; Pred. No. 0;
Matches 2349; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 357 taggatgacctccacctccagctctccagtttcaagtttgagagcatatgattgagcca 416
|||||
Db 1 taggatgacctccacctccagctctccagtttcaagtttgagagcatatgattgagcca 60
QY 417 agaagatgagctctgagcgagcagaggaagaagctgattttggagcgagctcccat 476
|||||
Db 61 agaagatgagctctgagcgagcagaggaagaagctgattttggagcgagctcccat 120
QY 477 ggaatcacagttccagagcgagacccgaaatctgcctccatagaataagttcaacctaa 536
|||||
Db 121 ggaatcacagttccagagcgagacccgaaatctgcctccatagaataagttcaacctaa 180
QY 537 ctaccgaaaggagaaacaggtgtcccaatcagcgagatccaaacagattttgacgagatcggt 596
|||||
Db 181 ctaccgaaaggagaaacaggtgtcccaatcagcgagatccaaacagattttgacgagatcggt 240
QY 597 ctcaatgcggtctcccgaggtgtcccgagagatctgtgacttccagagtaacctgag 656
|||||
Db 241 ctcaatgcggtctcccgaggtgtcccgagagatctgtgacttccagagtaacctgag 300
QY 657 caagaccagcaagtaacctcaacgagctcgaaatacagaagggctccacaaggttaagcgtg 716
|||||
Db 301 caagaccagcaagtaacctcaacgagctcgaaatacagaagggctccacaaggttaagcgtg 360
QY 717 cctgatgaagctgtgtctgaaccttaagagcaggtcaatgtcctgcgacttcgcaactgct 776
|||||
Db 361 cctgatgaagctgtgtctgaaccttaagagcaggtcaatgtcctgcgacttcgcaactgct 420
QY 777 gcaagatcagagagagctctgcaatctcctcaagcccttgtaattcccgatgcagatgta 836
|||||
Db 421 gcaagatcagagagagctctgcaatctcctcaagcccttgtaattcccgatgcagatgta 480
QY 837 ctattaccgagagcagacgagctctgcacatcgcgactgagaagaagagctgtcagtggt 896
|||||
Db 481 ctattaccgagagcagacgagctctgcacatcgcgactgagaagaagagctgtcagtggt 540
QY 897 gaaagctcctgtgtgagaaatggggccaatgtcgaatgccggagcctgcgacttccca 956
|||||
Db 541 gaaagctcctgtgtgagaaatggggccaatgtcgaatgccggagcctgcgacttccca 600
QY 957 gaaaggccaaggagactgtcttatttctggtgagctaacctcctcttgagcgacttgac 1016
|||||
Db 601 gaaaggccaaggagactgtcttatttctggtgagctaacctcctcttgagcgacttgac 660
QY 1017 caagcagtgagatgtgttaagctactcctctggaagaaccacacagccgcgacgtgca 1076
|||||
Db 661 caagcagtgagatgtgttaagctactcctctggaagaaccacacagccgcgacgtgca 720
QY 1077 ggcacatgactcccaaggcacaacagttcctgcagtcctagtatgatctcgacaactc 1136
|||||
Db 721 ggcacatgactcccaaggcacaacagttcctgcagtcctagtatgatctcgacaactc 780
QY 1137 agctgagaacaattgacatggtgagcagatgatatgatgggtctccaaagtggggcccg 1196
|||||
Db 781 agctgagaacaattgacatggtgagcagatgatatgatgggtctccaaagtggggcccg 840
QY 1197 cctctgcctaccgtgcagctctgagacatccgaacctgagagatctcaagctctgaa 1256
|||||
Db 841 cctctgcctaccgtgcagctctgagacatccgaacctgagagatctcaagctctgaa 900
QY 1257 gctgtgcgcgaaggaggaagatcgagatttcaagcacactctgcagcgagatttc 1316
|||||
Db 901 gctgtgcgcgaaggaggaagatcgagatttcaagcacactctgcagcgagatttc 960
QY 1317 agagactgagcaacttccgaaagttccacgagtggtgtgatagtgggtctgcggaggttc 1376
|||||
Db 961 agagactgagcaacttccgaaagttccacgagtggtgtgatagtgggtctgcggaggttc 1020
QY 1377 gctgtatgacctgtctctgtgagcagcgtgtgagagagactcaatgctgtcgtgagatcatg 1436

```

Db 1021 gctgtaagcctgctctgtgagcagctgtgaggaaactcagctgtgagatcatcgc 1080
Qy 1437 cttctcatcaagagagcccgacacagcaagatgctgtttggaaaccttgaacaaact 1496
Db 1081 cttctcatcaagagagcccgacacagcaagatgctgtttggaaaccttgaacaaact 1140
Qy 1497 gctcagaggaataagatgctgtctcatcccaagttcttcttaactctctgtgtatct 1556
Db 1141 gctcagagaggaataagatgctgtctcatcccaagttcttcttaactctctgtgtatct 1200
Qy 1557 gatctacatgttcatctctcatccgctgtgtcctacacatcagcctacccctgaagaagcagc 1616
Db 1201 gatctacatgttcatctctcatccgctgtgtcctacacatcagcctacccctgaagaagcagc 1260
Qy 1617 cggccctcaccggaagcggaggttgaagaaactccatgctgtgagcgggccaactctcttat 1676
Db 1261 cggccctcaccggaagcggaggttgaagaaactccatgctgtgagcgggccaactctcttat 1320
Qy 1677 cctgtcagagggagatcatcctcctcgtgagcagctgtgtatctctgagcggcagcagc 1736
Db 1321 cctgtcagagggagatcatcctcctcgtgagcagctgtgtatctctgagcggcagcagc 1380
Qy 1737 gttcatctgagatcgttcatagacagcactttgaatcctctctcgttccagggcct 1796
Db 1381 gttcatctgagatcgttcatagacagcactttgaatcctctctcgttccagggcct 1440
Qy 1797 gcttcaagaggtgttcccaaggtgtgtgttctcctgagcagatggttactcggccctgtc 1856
Db 1441 gcttcaagaggtgttcccaaggtgtgtgttctcctgagcagatggttactcggccctgtc 1500
Qy 1857 tctgtctcgtcgtgtgtcgtgctgctgagcctgtcttactataacgctggtctcagca 1916
Db 1501 tctgtctcgtcgtgtgtcgtgctgctgagcctgtcttactataacgctggtctcagca 1560
Qy 1917 cacaagcatctacagtgatcatcagaagaagtcactctgctggagacctgtcgtcttct 1976
Db 1561 cacaagcatctacagtgatcatcagaagaagtcactctgctggagacctgtcgtcttct 1620
Qy 1977 tctgatactctagttcttcttcttcttctgctgtcgtgtgagccctggtgagcctgaagca 2036
Db 1621 tctgatactctagttcttcttcttcttctgctgtcgtgtgagccctggtgagcctgaagca 1680
Qy 2037 ggtctgtgagcccgagcctctctacagccccaatgccaagagtcagtgagccccaatga 2096
Db 1681 ggtctgtgagcccgagcctctctacagccccaatgccaagagtcagtgagccccaatga 1740
Qy 2097 gggacagagagagagagagagagagagagagagagagagagagagagagagagagagag 2156
Db 1741 gggacagagagagagagagagagagagagagagagagagagagagagagagagagagag 1800
Qy 2157 ggtcttcaaatcacaacatcgagatggtgagcgtgtgagccttccaggaagcagctgacattcg 2216
Db 1801 ggtcttcaaatcacaacatcgagatggtgagcgtgtgagccttccaggaagcagctgacattcg 1860
Qy 2217 cggcagtggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2276
Db 1861 cggcagtggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 1920
Qy 2277 catgtctcatcgccctcatagagagagagagagagagagagagagagagagagagagagat 2336
Db 1921 catgtctcatcgccctcatagagagagagagagagagagagagagagagagagagagagat 1980
Qy 2337 cgggaagcgtcagaaagcagatctctgtctgtgagatgagtgagtgatgtgtgtgtgtgtgt 2396
Db 1981 cgggaagcgtcagaaagcagatctctgtctgtgagatgagtgagtgatgtgtgtgtgtgtgt 2040
Qy 2397 gaagaagcagcggagcaggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2456
Db 2041 gaagaagcagcggagcaggtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2100
Qy 2457 tgaagcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2516

```

```

Db 2101 tgaagcgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2160
Qy 2517 taagctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2576
Db 2161 taagctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2220
Qy 2577 ggtcttccctcccaagagagatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2636
Db 2221 ggtcttccctcccaagagagatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2280
Qy 2637 gctctcagctcacaatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2696
Db 2281 gctctcagctcacaatgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgt 2340
Qy 2697 tcttcccaacc 2707
Db 2341 tcttcccaacc 2351

```

RESULT 9

AAZ07116

ID AAZ07116 standard; cDNA; 2348 BP.

AAZ07116;

08-OCT-1999 (first entry)

Human vanilloid receptor homologue VANILREP2 polymorphic variant PVP-1.

Human; vanilloid receptor homologue; VANILREP2; polymorphic variant; PVP-1; therapy; diagnosis; chronic pain; neuropathic; postoperative; rheumatoid arthritis; neuralgia; algesia; nerve injury; ischemia; neurodegeneration; stroke; incontinence; inflammatory disorder; ss.

Homo sapiens.

Location/Qualifiers

Key 5..2296

FT CDS /tag= a /product= "VANILREP2 polymorphic variant PVP-1"

FT FT /note= "vanilloid receptor homologue"

PN WO937765-A1.

PD 29-JUL-1999.

PF 25-JAN-1999; 99MO-EP00420.

PR 20-JAN-1999; 99GB-0001209.

PR 27-JAN-1998; 98EP-0300549.

PR 26-OCT-1998; 98GB-0023421.

PA (SMK) SMITHKLINE BEECHAM PLC.

PI Davis JB, Duckworth DM, Hayes PD;

DR WPI; 1999-479049/40.

PS P-PSDB; AAV29471.

PT New human vanilloid receptor homologues (VANILREP2)

XX Claim 9; Page 34-35; 47pp; English.

The present sequence encodes a human vanilloid receptor homologue VANILREP2 polymorphic variant PVP-1. VANILREP2 can be used to diagnose disease or susceptibility to disease related to expression or activity of VANILREP2 polypeptides. VANILREP2 may be used to treat diseases including pain, (for example chronic, neuropathic, postoperative, rheumatoid arthritis), neuralgia, algesia, nerve injury, ischemia, neurodegeneration, stroke, incontinence, and inflammatory disorders.

Sequence 2348 BP; 487 A; 683 C; 673 G; 505 T; 0 other:


```
DB 2098 tagagcgtgtgtgttcagggttgagagagtggaactggtgcttcattgggagagacgctgcc 2157
OY 2517 taagcgtgttgagagccctcagaagcaggtgtccctcgaactctgagaaacctgtcct 2376
DB 2158 taagcgtgttgagagccctcagaagcaggtgtccctcgaactctgagaaacctgtcct 2217
OY 2577 ggttcctccccaagagagatgagatgtgtcctctgagaaactatgtgccctcca 2636
DB 2218 ggttcctccccaagagagatgagatgtgtcctctgagaaactatgtgccctcca 2277
OY 2637 gctcctccagtcgaactatgagcagatgagcagagagagccagagacagcagagaga 2696
DB 2278 gctcctccagtcgaactatgagcagatgagcagagagagccagagacagcagagaga 2337
OY 2697 tcttcctaac 2707
DB 2338 tcttcctaac 2348

RESULT 10
AA87478
ID AA87478 standard; cDNA; 2736 BP.
XX
AC AA87478;
XX
DT 08-OCT-1999 (first entry)
XX
DE Rat vanilloid receptor-related polypeptide 1 (VRP-1) cDNA.
XX
XX Vanilloid receptor-related polypeptide 1; VRP-1; VR2;
KW capsaicin receptor; VR1; rat; vanilloid; analgesic; pain;
KM inflammation; therapy; diagnosis; ss.
XX
OS Rattus rattus.
XX
FH Key Location/Qualifiers
FT CDS 330..2615
FT /tag= a
XX
PN MO9937675-A1.
XX
PD 29-JUL-1999.
XX
PF 22-JAN-1999; 99WO-US01418.
XX
PR 22-JAN-1998; 98US-0072151.
XX
PA (BEGC ) UNIV CALIFORNIA.
XX
PI Brake AJ, Caterina M, Julius DJ;
XX
DR MPI: 1999-469113/39.
XX
DR P-PSDB; AAY06556.
XX
PT New isolated capsaicin receptor polypeptide and related nucleic acid
PT - useful for detecting vanilloid compounds, identifying modulators,
PT and in diagnosis or treatment of e.g. pain and inflammation
XX
XX Claim 8: Page 80-81; 120pp; English.
XX
XX This is the nucleotide sequence of cDNA coding for rat vanilloid
XX receptor-related polypeptide 1 (VRP-1 or VR2). The cDNA was
XX isolated from a brain cDNA library. VRP-1 (AAY06556) is an example
XX of a capsaicin receptor-related polypeptide of the invention. It
XX is not activated by capsaicin or heat, but may interact with the
XX novel capsaicin receptor VRI (see AAY06555). The invention provides
XX vanilloid receptor polypeptides and polynucleotides, including
XX capsaicin receptor-related polypeptides and polynucleotides, as well
XX as expression vectors, host cells and transgenic animals. It also
XX provides a method of using such receptors to identify vanilloid
XX compounds in natural products or to screen candidate compounds that
XX modulate capsaicin receptor function for use as analgesics (vanilloid
```

```
CC analogues, therapeutic antibodies, antisense oligonucleotides,
CC capsaicin receptor-encoding polynucleotides for gene therapy),
CC flavour-enhancing agents, etc. Capsaicin receptor-related
CC polypeptides and specific antibodies can also be used for the
CC diagnosis and treatment of human disease and pain. Polynucleotides
CC can be used as probes to determine the structure, function, location
CC and expression of capsaicin receptor, receptor subtypes and capsaicin
CC receptor-related polypeptides in mammals (including humans) and to
CC investigate associations between disease states or clinical disorders
CC (particularly those involving acute and chronic pain or inflammation)
CC and defects or alterations in receptor structure, expression or
CC function.
XX
XX Sequence 2736 BP; 615 A; 780 C; 728 G; 613 T; 0 other;
XX
XX
XX Query Match 55.0%; Score 1544.2; DB 20; Length 2736;
XX Best Local Similarity 77.9%; Pred. No. 0;
XX Matches 2016; Conservative 0; Mismatches 498; Indels 73; Gaps 10;
OY 222 gcaagccgacgagcgtggtcagcgtgaggggtccagtcagagcccaacagcagcgca 281
DB 201 ggcgcgcacacactgtgttcagcgtgaggggtccagccagcgtgcctcggtat 260
OY 282 gctggaggaagacagagacccttgacatctccatctgcaagaggtcctgtgacgca 341
DB 261 g-----agagaggaacttaacatctccatctcagaggttcagctgtaaga 311
OY 342 ggaagcctctctctcagatgatacctcaccctccagctcagtttcaagtttgaagac 401
DB 312 gcatcctctc-ctctcagatgatacctcagcctccagcccccagcttcaagcttgagac 370
OY 402 atgagtgagagcagagagatgagctctgagcgagcagagaaagctgatttggag 461
DB 371 ttccagtgagatgagagagagcagatgctgagtgagtgagcaaggggaagcaga ----- 421
OY 462 cggagctcctccatgagatgacaggttcagagcgagagccggaatctgcctccatag 521
DB 422 ---accgccccatgagtgacacattccagagggagcggaattcctccctcagat 478
OY 522 aagagtcacactcaactacagaaaggga-----acagggcgacgtcagcc 566
DB 479 caaagtgaacctcaactatcaaaagagacctccctaaacactctgcccagcagcaga 538
OY 567 gatatccaaacgatttgacagagctgcttcaattgagtgctcccgagggtgcccca 626
DB 539 ggaagcagatcggttgacagctgacagcagactctcagtggtctcccgagggtcccca 598
OY 627 ggaatgctgagacttcagagtaacttgacaagacagcagaagtacccaagcagactgga 686
DB 599 ggaactgactgagctgtagaatacctgcgtggaacagcagaagtaactcagactctgc 658
OY 687 atacaagagggctccacaggtgaagcgtgctgtagaaggtctgtgctaaactaaga 746
DB 659 atacaagagaggtccacaggtgaagcgtgctgtagaaggtctgtgctaaactaaga 718
OY 747 cgaagtcagctgctgacttcctccactgctgtagatgacagcagcagcctcgaatcccta 806
DB 719 tgggtgcaatgctgactatgctgcgtgtgctgtagatgacagcagcagcctcgaatcccca 778
OY 807 gccctgtgtaatgcccagtgacacagatgatactaacgagagccacagcgtctgcaat 866
DB 779 gccctgtgcaatgcccagtgacacagatgatactaacgagagccacagcgtctgcaat 838
OY 867 gccctgtgagagagagctgtagatgtagagcctcgtgtagagagagagagagagagag 926
DB 839 gccacataagagagagagctgtagatgtagagcctcgtgtagagagagagagagagag 898
OY 927 gtagtcggcggtcgtgagcgtcttcacagagggccaaagagagagagagagagagag 986
DB 899 tcaacctcgagcgtgtgagcgtcttcacaaagagcacaagagagagagagagagagag 958
OY 987 tgaagtaacctctctcttggtgcgcttgacacaaagagagagagagagagagagagag 1046
```


OY	1824	ttctctgagccatcgagatgagatgacccctgcctctgctctgctctgctgctgctgctgct	1883
Db	1799	cttcaatgagaaactcgaaatgaaacttaaccctctgctgagtgtatccctcaagatgacggtgct	1858
OY	1884	gaaacctcttactatacaagctgagcttccagacacacagacatctacaagtgtcatagatcca	1943
Db	1859	gaacctcttactatacaaggggcttctcagaacacagacatctacagtgtcatagatcca	1918
OY	1944	gaagatcatccctgcggagacctgctgcgtctctctctatcatctaatgactctcttcctg	2003
Db	1919	gaagatcatccctgcggagacctgctgcgtctctctctatcatctaatgactctcttcctg	1978
OY	2004	cttctgcgtatgacctggtgagaccttcgagccagagagcttgtagccctccagagcttctacaag	2063
Db	1979	cttctgcgtatgaccttcaatgaagctcttgagccagagagccccaagcttcccaagcccttgaga	2038
OY	2064	cccccaatgcacagagatcgaatgacagcccaatgtagagagacagagagacagagggccaacgggac	2123
Db	2039	taacaactccaacagtgagccggaacagccacggcttgtagccagagggagggg-----ccaagc	2092
OY	2124	ccagtatcaggggtatcccttgtaagcctcctcttgagctcttcaaatccacatccgcatatgg	2183
Db	2093	tccaatcatcgagacattctgattgatactccctccatagagctgttcaagatccaacatttgatagg	2152
OY	22184	cgagactgagcccttccagagagagctgtaagcttccgcgggacatagtgctgcgtcgtcgtccgac	2243
Db	2153	ggagatctgaccttccagagaaagaaagctctgattcttcgggggttggtaccctgcgtctgacctgac	2212
OY	2244	ctaaagctgctcacaactacaatccctctgctctcaacatgctcatcagccctccatagagacgagac	2303
Db	2213	ctaaagctctctcacaactacgctcctgctctcaacatgctcatcattgctctcatagagagaaac	2272
OY	2304	cgtaacaagtgctccgaactgtaacagctgtagagcatctgtaagctctgacgaagaccatctctgt	2363
Db	2273	tgtaacaacaaagctgtctgtaacaacagctgtagagcatctgtaagatgtagcaagaagcatctctgt	2332
OY	2364	ccctgtagaataggaataatgagctattggtggtgc-- -aggaagaagacagcggtgaggtgcat	2420
Db	2333	ctctgtagaataggaataatgagctattggtggtgcggaaggaagaacaacatcgtagaaggagagct	2392
OY	2421	gctgaaccggttggaactaagacacagatgtagcagcccggaatgtagcgctgtgtcttccataggtgta	2480
Db	2393	gctgaagaagctcggaaccagggggatgtagtaaccctgatgtagcgctgtgtcttccaggtgta	2452
OY	2481	ggagatgtaaacctggtctctcatagggagacagacgctgctactacgctgtgtgtagagcccgtaag	2540
Db	2453	ggaaagataaacttggcgtctgctgtagaagaagactcttccacactatattgtagatccaatcag	2512
OY	2541	ggcagcgtgctccctcgaaactctcgaaagaccctgtccctgctgttccctccccaagaggagatga	2600
Db	2513	ggcagcagcataactcgtgtataaagaagac-----caactcttaaacgggggaa	2580
OY	2601	ggaatgctgctccttgtagaanaaactatgtgcccgttccagactcctccatgccaactgatatggcc	2660
Db	2561	gaacagcgtcctcagagaaagaaacatctgccttcaagctcagctccatcccttgatggcc	2620
OY	2661	cagatgcagcagagagggccag -aaggaaagacagagagatcttccaacacacatctgctgac	2719
Db	2621	cagatgcagcagagagggctgtagcagaaatgtaggtatcttccagccacacacagagag -	2678
OY	2720	tcttggttcccaatgtaattcttggtgccaatatataatttcaactcaacacaaaaaaaaa	2779
Db	2679	-----ctactgaaatttggtggaataataataatttcttcttgcatataaaaaaaaaa	2729
OY	2780	aaaaaaa	2786
Db	2730	aaaaaaa	2736

```

AC      AAA30256;
XX
XX      05-SEP-2000 (first entry)
XX
XX
XX
XX      Rat partial VR-2 coding sequence.
DE
XX
XX      VR-2: rat: vanilloid receptor; nociceptor; pain signalling;
KW      hyperalgesia; musculoskeletal disorder; neuropathic pain;
KM      gene therapy; ss.
XX
XX      Rattus sp.
OS
XX
XX      .Location/Qualifiers
FH      Key                2..1666
FT      CDS               /*tag=^a
FT                               /product= "VR-2"
FT                               /partial
XX
XX      W0200029577-A1.
PN
XX      25-MAY-2000.
PD
XX
XX      12-NOV-1999;    99WO-US26701.
PF
XX
XX      13-NOV-1998;    98US-0108322.
PR      28-DEC-1998;    98US-0114078.
PR      26-FEB-1999;    99US-0258633.
PR      19-OCT-1999;    99US-0421134.
XX
XX      (MILL-) MILLENNIUM PHARM INC.
PA
XX
XX      Curtis RAJ;
PI
XX      WP1: 2000-387790/33.
XX
XX      P-PSDB; AAI97360.
DR
XX
XX      New capsaicin/vanilloid receptor polynucleotides and polypeptides, used
PT      to modulate pain signalling mechanisms -
XX
XX      Claim 1, Fig 4; 183pp; English.
XX
XX
XX      The present sequence is the coding sequence for the rat
CC      capsaicin/vanilloid receptor VR-2, which is involved in pain signalling.
CC      The sequence was isolated by searching a dorsal root ganglion library for
CC      genes encoding novel receptors of the capsaicin/vanilloid family. The
CC      human version of this gene is found at chromosome 17p11-12, a region
CC      which has been associated with myasthenia gravis, Smith-Magenis syndrome,
CC      CMD5, Cone-rod dystrophy, choroidal dystrophy, central areolar and
CC      retinal cone dystrophy, and it is possible that the human protein may be
CC      used to treat or diagnose these disorders. In addition, the human gene,
CC      protein and its antibodies can be used to diagnose and treat
CC      hyperalgesia, inflammation, infection, ischemia, joint pain, tooth pain,
CC      headaches, pain associated with surgery or neuropathic pain, possibly via
XX      the use of gene therapy.
XX
XX      Sequence 1794 BP; 396 A; 499 C; 474 G; 425 T; 0 other:
S0

Query Match          39.2%; Score 1102.4; DB 21; Length 1794;
Best Local Similarity 78.5%; Pred. No. 3e-224;
Matches 1409; Conservative 0; Mismatches 351; Indels 36; Gaps 6

```

Db	138	tggttaatgatctgcagataactgcgtcgagaaacagtgcccttggttgatccaacatgtaacga	197
Oy	1175	ggtctccccaagctctggggccgcgcctctctctcctcaacgtgacagtttgagaaacatccgaac	12344
Db	198	ggcttctacaatatggggcgcgccctctctgcgcccatctgtagctcttgaggaatactccaac	257
Oy	1235	tgccagatctacgcctctgaagcttgccgcgcgaaggaaggaagatcgatatttcagc	1294
Db	258	accagaagcttcaacaccccttgaaactagccgcgaaggaagcaaaatcgagaatttccaagc	317
Oy	1295	acatccctcgaacggaggttttccatagagactgagca---cccttccgaagaattcatccag	1351
Db	318	acattctgcagcgggaatttctctcagacgcgtaccagcccttcccgaaagtcttaactggt	377
Oy	1352	ggtgcatabyggccctgtccgggtgctgcgctgatatacccttgctctctgttgagacagctgag	1411
Db	378	ggtgttaacgctcgtgtgcgggtatcgctgtaacgaactgctctctctgttgagacagctgagaa	437
Oy	1412	agaactcagtgcttggaatacatatgctcttcatatgcaagaagcccgacacgcgaatg	1471
Db	438	agaactcgggtcgtgagatcatcatcgcttcttcatgcaagagcccgacacgcgcacgtatg	497
Oy	1472	tcgttttgagccctctgaacaaactgctggaagcggaatgggatctgtcattcccccaagt	1531
Db	498	tggttttgaaacccactgaaacaagctctctcgaaagaaatggagatccgctctcaaat	557
Oy	1532	ctctcttaaaccttctctgtgaatactgatatactatgttcatcttcaacgcgctgtgtccacc	1591
Db	558	ctctcttaactctgcgtctactgttctgtataatgtaacttcaactcaacgctgtgtccacc	617
Oy	1592	atcagcctaacccttgaaagaagcagagccgcctccaactgaaagcggaggttgaaactca	1651
Db	618	accagccttcccttgatcaagcagacatccctctcatcaaaagcgacttltggagatcca	677
Oy	1652	tgctgcgtgaacggacacatcttcatctctgaaggggatcttaactctctgtggggccagc	1711
Db	678	tgctgcgtcgtggccacaaattctgaatccctgctgtgggtatattcaactcttaacgtggccagc	737
Oy	1712	tggtgaactcttgccggcgccagcgtgttatatcgtgagctcgttcatagacaagctacttg	1771
Db	738	tggtgaacttltggcgccggcgctgtttatctgagatccatcatatgacaagctacttg	797
Oy	1772	aaatcctctctctgttccaaagccctgcacaaagtgtgtccaaagtgcgtgttctccbg	1831
Db	798	aaatcctcttctctctcagcgtctgcacaaagtgtgtccaaagtgcgtgcgttccatg	857
Oy	1832	ccatcaggtgtgaactgcgcctctgcgtgtgtgtcgtcgtgtgtgtgtgtgtgtgtgtgtgtgt	1891
Db	858	agactgaattgttactcaacccctctcagtgatlatcccttaagtgctgtggcgttgaaactgc	917
Oy	1892	tttaactatacgtggtcttccagacaacaggaactatacagttcatatgtatccagaaggtca	1951
Db	918	tttaactatacagcgggtcttccagacaacaggaactatacagttcatatgtatccagaaggtca	977
Oy	1952	tcctgctggagactgcgtctctctctctcatctaatcttaagttcttcttcttgctgtgt	2011
Db	978	tccttgcagacgtctccgttctctctgcgtctcaactcgtgtcttctcttcttgctgtgt	2037
Oy	2012	tagccctggtgagccttgagcccaaggaagcttggcgcccgccaagctctctcaagcccccaatg	2071
Db	1038	tagcccttagtataagctttagagagaagagcccggaatgcacaaaccccttaaaataataact	1097
Oy	2072	ccacaagatcagtgacaaacccatagaaagagaagagacagagcgaagcgccacagttaca	2131
Db	1098	ccacaagatcagagaaacagccacagctgtggccagagaggaagag-----ccagatccataac	1151
Oy	2132	ggggtatcttggaagcctctcttggaagcttccaataatccaactcggcatctggcgagctgg	2191
Db	1152	ggagcattcttgagctctccctctagagctgttcaagttaaccaattgtatbtggggagctgg	1211
Oy	2192	ccctccagagcagctgcgaactctcgccgcgacatggtgctgctgctgcgtctgagctacgtgc	2251
Db	1212	cttccacagaaacagctgcgttcttccgtgggggtgtgctctctgctgtgctgttgcctacgtcc	1271

QY	2252	tgctcaacctacatccctctctctcctaacaatgctcatcgccctcatatgagcgagacgctcaaca	23111		
Db	1272	tctctacctaactgcctctctctcctaacaatgctcatcgctctctcatatgagcgaaactgcaacc	13313		
QY	2312	gtgtcgccactgaacagctctgagacatctcgagaagctgacagaagaacacatctctgtccctgagga	23717		
Db	1332	acgttgcctgtaacaacaacgctcgagacatctcgagaagctgacagaagaacacatctctgtccctgagga	13921		
QY	2372	tggagaaatgagctatctgtgtgtgc--aggagaagaagcagcgagctgtgtatgctgacg	2428		
Db	1392	tggagaaatgagctatctgtgtgtgc--aggagaagaagcagcgagctgtgtatgctgacg	1451		
QY	2429	ttggcactcaagccacgatacgagcagcccgagatgagcgctgtgtctcaaggtctgagagagtgta	2488		
Db	1452	tccgagacacagggggagctgagtaacccttgatgagcgtgtgtcttcacgggtctgagagagtgtaa	15111		
QY	2489	actgaggtctcatgaggacacagcgtgctctacgcgtgtgtgtgaagaccgctcaagggcgagctg	2548		
Db	1512	atgtgagcgtctgtggagaaagacatctccacacctcatctgagatccatcagagcgacagca	15711		
QY	2549	tcacctgaactctcgagaacacctgtccctgtcctgtcctccctcccaaggagatgagatgtg	2608		
Db	1572	tcacctgtgataaagaagaacc-----caacctctaaaccgggaggaacagctg	1619		
QY	2609	cctcttgaggaanaactatgtgcccgtccagctcctccacgctccacagatgagccccagatgca	2668		
Db	1620	cctcaagaggaagacacatctgccccttcaggtctccctcagctcccccgtatggtcccaagatgca	1679		
QY	2669	gcaggaagggccag-aggacacagacagagagatctctccacaacacatctgtgtcgtctg	2727		
Db	1680	gcagcagagctgtgcagaggtgtgtagtggaatctctccagccacacacagag-----	1729		
QY	2728	cccaagtgaattctgtgtgcsaataatatatttcaactaactcaaaaaaaaaaaaaa	2783		
Db	1730	ctactgaatttgtgtgaataataatatatttcttgcataaaaaaaaaaaaaa	1784		
RESULT 13					
AA30255	AAA30255 standard; cDNA; 1489 BP.				
AC	AAA30255;				
XX	05-SEP-2000	(first entry)			
DT	Human VR-2 (alternate form) coding sequence.				
XX	VR-2; human; vanilloid receptor; nociceptor; pain signalling;				
KW	hyperalgesia; musculoskeletal disorder; neuropathic pain;				
KM	chromosome 17p11-12; gene therapy; ss.				
XX	Homo sapiens.				
OS					
XX	Key				
FF	CDS	Location/Qualifiers			
FT		3..1313			
FT		/*tag= a			
FT		/product= "VR-2 alternate form"			
FT		/partial			
XX	WO200029577-A1.				
XX	25-MAY-2000.				
XX	12-NOV-1999;	99MO-US26701.			
XX	13-NOV-1998;	98US-0108322.			
PR	28-DEC-1998;	98US-0114078.			
PR	26-FEB-1999;	99US-0258633.			
PR	19-OCT-1999;	99US-0421134.			
XX	(MILL-) MILLENNIUM PHARM INC.				

